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Mendelian disorders are a set of heritable phenotypes that come at a significant cost for 
patients, their families, and the healthcare system.  Here we describe and implement 
strategies to determine the genetic basis of unexplained Mendelian disorders through 
next-generation sequencing. Using whole-exome sequencing, we found that a novel 
heterozygous variant in COL2A1 underlies Stanescu dysplasia, and that biallelic variants 
in PCYT1A cause spondylometaphyseal dysplasia with cone-rod dystrophy (SMD-CRD). 
In addition to detecting causal variants for phenotypes of interest, next-generation 
sequencing has the potential to reveal incidental findings in genes unrelated to a patient’s 
primary phenotype.  We find that incidental findings arise frequently in clinically 
actionable genes, yet our ability to interpret them is extremely limited, highlighting the 
need for improved and standardized variant classification methods. Finally, we generated 
and characterized various cellular models for the characterization of SMD-CRD alleles in 
PCYT1A. Our studies suggest that full or partial loss of PCYT1A expression has variable 
and cell-type specific consequences, resulting in altered lipid metabolism and lipid 
droplet formation, accelerated chondrocyte differentiation, and varying degrees of 
PCYT1A loss-of-function.  We conclude that concerted efforts are required to fully 
elucidate the genetic and mechanistic bases of Mendelian phenotypes, and that sustained 
efforts are required for the accurate interpretation of human genetic variation detected by 
next-generation sequencing studies.  
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Chapter 1: Introduction 
The utility of studying rare Mendelian disorders 
Mendelian disorders are a collection of heritable phenotypes transmitted from 
parents to their children according to Mendelian modes of inheritance. Approximately 8% 
of all viable human births have a Mendelian condition that manifests by adulthood, and 
Mendelian disorders affect a total of 25 million Americans (Chong et al., 2015).  Many of 
these disorders are extremely debilitating and are of high burden for patients, their 
families, and the healthcare system (Angelis, Tordrup, & Kanavos, 2015). Mendelian 
disorders range from severe, multi-systemic phenotypes such as Hutchinson-Gilford 
progeria syndrome to milder, more targeted phenotypes such as isolated strabismus.  
Mendelian disorders vary in their population frequencies, and in some instances the same 
disorder can vary in frequency depending on the population being studied, as pathogenic 
alleles may be enriched in specific populations.  An example of this is Tay-Sachs disease, 
for which 1:300 individuals in the general population are heterozygous carriers of 
pathogenic alleles, in contrast to the 1:30 heterozygous carrier rate in the Ashkenazi 
Jewish population (MIM 272800; www.omim.org).  
Because many monogenic Mendelian disorders affect only small numbers of 
individuals, the utility of studying them comes into question, especially when research 
resources are limited.  As a form of justification, we can think of Mendelian phenotypes 
as naturally occurring model systems.  They enable us to see how an isolated genetic 
defect can impact larger biological processes, and in this way dissect systems which 
would otherwise be far too complex to understand all at once.  Furthermore, studying 




the population at large.  An example of this is Brown and Goldstein’s discovery of 
biallelic variants in the gene encoding the low-density lipoprotein receptor in individuals 
with familial hypercholesterolemia (Goldstein & Brown, 2015). By studying this severe 
pediatric disorder, Brown and Goldstein were not only able to dissect more generalizable 
mechanisms for LDL uptake and cholesterol metabolism, but also were able to implicate 
heterozygous LDL receptor variants in less severe cardiovascular phenotypes affecting 
1:500 individuals. Finally, the basic research that stemmed from uncovering this genetic 
defect led to the discovery and implementation of statin drugs, which have been used to 
reduce LDL levels and prevent cardiovascular disease in the population at large.  Thus, 
understanding extreme cases that occur naturally in the population can ultimately lead to 
broader clinical applications and help us to understand genetic variation as a whole.   
 
Application of whole-exome and whole-genome sequencing to explain rare 
Mendelian disorders 
Next-generation sequencing has ushered in a brave new era for diagnosis and 
treatment of Mendelian disorders.  Previously, disease gene discovery relied on 
hypothesis-driven testing for disease-associated genes and pathogenic variants, and as 
such was biased toward existing knowledge of variation in humans and other model 
systems.  Exome and genome sequencing enable unbiased evaluation of genetic variation 
in order to identify candidate causal variants, and thus enable the discovery of completely 
novel mechanisms for disease. Less than a decade ago, Ng et al. demonstrated that exome 
sequencing can be applied to uncover the genetic basis of a Mendelian disorder (S. B. Ng 




In 2012, the NIH, NHGRI, and NHLBI collectively initiated the Centers for 
Mendelian Genomics (CMGs), a collection of centers across the US dedicated to finding 
the genetic bases of unexplained Mendelian disorders through next-generation 
sequencing. One of the CMGs is the Baylor-Hopkins Center for Mendelian Genomics, 
led by investigators at Johns Hopkins University and Baylor University.  As an initial 
step toward identifying all genetic variants and genes contributing to Mendelian 
phenotypes, the CMGs began by applying exome sequencing to understand the genetic 
basis of a variety of Mendelian disorders.  Although the exome only comprises ~1-2% of 
the genome, variants in protein-coding sequences are responsible for the majority of 
explained Mendelian disorders to-date (Chong et al., 2015).  Furthermore, exome 
sequencing is currently less expensive than genome sequencing, so a larger number of 
phenotypes can be investigated by applying this approach as an initial step. As of 
December 16, 2017, http://mendelian.org/mendelian-traits-numbers stated that 63% of 
currently known Mendelian phenotypes have a known molecular basis, and 18% of 
human genes have been shown to harbor variants that cause a Mendelian phenotype. 
Thus, we are making great headway in understanding Mendelian phenotypes and their 
genetic bases, but much of the exome still remains unexplained. 
Hurdles for gene and variant discovery and functional characterization 
Though next-generation sequencing together with analytic approaches that 
incorporate genetic and genomic information have solved many Mendelian disorders, 
several factors have prevented complete success of these studies.  First, these disorders 
typically are rare, which prevents obtaining sufficient statistical evidence for genetic 




find.  In some cases, unaffected or more mildly affected family members may also be 
mosaic for variants of interest, which confounds analyses. Second, our ability to 
phenotype is limited by the systems subjected to clinical examination, the expertise and 
thoroughness of examination, and the age of the patients being studied.  In some cases, 
phenotypes are missed simply because clinicians don’t yet know to look for them, or 
because they have not yet manifested in a clinically recognizable way.  Both these factors 
confound our ability to cluster families for analytical purposes, or to perform proper 
segregation analyses within families for late-onset conditions.  
Moreover, there is often phenotypic overlap among genetically disparate disorders 
(for instance, joint hypermobility in multiple forms of Ehlers-Danlos as well as other 
disorders).  Another issue is locus heterogeneity (variants in different genes causing 
similar phenotypes), since the same candidate gene may be mutated in only a single 
family.  Furthermore, allelic heterogeneity (different variants in the same gene observed 
in independent individuals with the same phenotype) complicates variant interpretation, 
as many variants fall in disease-associated genes but are not pathogenic in themselves.  
We will explore this concept further in Chapter 3.   
Nearly a quarter of all phenotype-associated genes have been described in 
connection with more than one Mendelian phenotype, which further confounds our 
ability to interpret variants (December 16, 2017, http://mendelian.org/mendelian-traits-
numbers).  I will provide an example of this in Chapter 5 through the case of biallelic 
variants in PCYT1A causing three distinct or partially overlapping phenotypes.  A 
separate problem is that some disorders appear to follow classic Mendelian patterns of 




variable expressivity, which pose additional challenges for segregation analyses. 
Furthermore, genes may require environmental interactions in order for protection against 
disease or to spur disease manifestation (e.g. fava bean consumption leading to hemolytic 
anemia in association with G6PD deficiency; MIM 305900). 
Another hurdle is obtaining strong evidence for variant causality, particularly 
given a large list of candidate variants.  For instance, in conducting exome sequencing of 
an affected parent and child with an autosomal dominant disorder, we may find ~100 rare 
(minor allele frequency < 0.01), functional (coding or splice site) variants shared between 
both affected individuals.  I will discuss such a case in Chapter 2. Some genes such as 
TTN also have large coding sequences, and as such are larger targets for mutation.  This 
makes it extremely difficult to interpret variation that arises in these genes.  In some 
instances, certain variants may also be in linkage disequilibrium with truly pathogenic 
variants, which can lead to improper flagging of variants as causal.  Finally, strong 
candidate variants may be identified but lack additional supporting functional evidence to 
implicate them in disease pathogenesis.  This issue can be compounded by inaccessibility 
of relevant tissue types for certain disorders. Finally, although exome sequencing 
enriches for protein-coding regions, it excludes putatively functional noncoding elements 
such as promoters or enhancers, as well as much of the 3’ and 5’ untranslated regions and 
introns.  Our ability to detect copy number variants as well as structural variants from 
exomes is also limited.  In combination, all these factors have barred us from having a 
more complete understanding of Mendelian disorders and their genetic bases.  However, 





Finally, once candidate variants have been identified, detailed functional studies 
must be conducted in order to trace the path from a genetic defect to its corresponding 
disease mechanism. Although this process may be straightforward, biological systems are 
often more complex than we anticipate. The consequences of genetic variants may be 
tissue- or cell-type-specific, and disease mechanisms may not be overtly connected to the 
known functions of candidate genes, as we will see in Chapter 5.  Though riddled with 
challenges, increasingly sophisticated methods for functional studies are necessary for 
truly understanding Mendelian disorders and treating them to improve patient outcomes.  
Next-generation sequencing studies have invigorated a whole new cycle of functional 








Chapter 2: Novel COL2A1 variant (c.619G>A, p.Gly207Arg) 
manifesting as a phenotype similar to progressive 
pseudorheumatoid dysplasia and spondyloepiphyseal dysplasia, 
Stanescu type 
Chapter 2 is reprinted from the final accepted version of the journal article: 
Jurgens J, Sobreira N, Modaff P, Reiser CA, Seo SH, Seong MW, Park SS, Kim OH, Cho 
TJ, Pauli RM. (2015). Novel COL2A1 variant (c.619G>A, p.Gly207Arg) manifesting as a 
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dysplasia, Stanescu type. Hum Mutat. 36(10): 1004-8. 
Julie Jurgens’s Contributions: Exome sequence analysis and identification of COL2A1 as 
primary candidate gene for this family’s condition; Sanger validation of variant and 
segregation analysis; identification of second family with the same COL2A1 variant and 
skeletal dysplasia phenotype at an ASHG annual meeting; coordination of efforts 
between clinicians and researchers in U.S. and Korea for phenotypic comparison of 
probands, correspondence, and ongoing collaboration; conceptualization and drafting of 
manuscript and figures; coordination of revisions from other co-authors; coordination of 
submission process; drafting of response to reviewer comments and integration of 
additional responses from other co-authors; manuscript finalization with journal for 
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Introduction 
Progressive pseudorheumatoid dysplasia (PPRD; MIM 208230), is a painful, disabling 
autosomal recessive skeletal dysplasia accompanied by pseudorheumatoid arthritis that 
manifests in childhood and inexorably worsens. Features include platyspondyly, 
epimetaphyseal expansion, and progressive stiffness and swelling of the joints (Garcia 
Segarra et al., 2012). Hurvitz et al. (1999) implicated variants in WISP3 (Wnt-1-inducible 




variants were found in a simplex case in this cohort (Family 6), suggesting locus 
heterogeneity (Hurvitz et al., 1999).  
 Spondyloepiphyseal dysplasia (SED), Stanescu type, is distinguished by painful, 
progressive joint space narrowing, joint contractures, platyspondyly, and epimetaphyseal 
dysplasia with pronounced femoral coxa valga and normal stature. This disorder was first 
described by Stanescu et al. (1984) in a male proband born of unaffected parents, making 
the mode of inheritance indeterminate. Subsequently, Nishimura et al. (1998) described 
two families with multiple affected generations and autosomal dominant transmission 
(Nishimura et al., 1998). As noted by Nishimura et al. (1998), SED, Stanescu type is 
likely underdiagnosed, perhaps due to shared features with other dysplasias. Neither the 
genetic basis of this disorder nor is its relationship to PPRD is clear. 
Czech dysplasia (MIM 609162) is caused by a heterozygous c.823C>T, 
p.Arg275Cys variant in the type II alpha-1 collagen gene COL2A1 (MIM 120140). While 
also characterized by early-onset, progressive arthritis and skeletal dysplasia, it is 
clinically distinguishable from PPRD by shortened metatarsals in all described 
individuals (Marik, Marikova, Zemkova, Kuklik, & Kozlowski, 2004). 
Here we describe three patients from two families harboring a novel heterozygous 
variant in COL2A1 (RefSeq NM_001844.4: c.619G>A, p.Gly207Arg), with similar 
phenotypes. 
Clinical Description 
The proband of Family 1 (Table 1) was previously reported as the simplex case of 
family 6 by Hurvitz et al. (1999).  She is the product of unaffected, non-consanguineous 




never to hop or run. A waddling gait was initially assessed at 4 years of age, prompting 
concerns of limb weakness, but extensive evaluation demonstrated no neuromuscular 
abnormality. Joint pain began around 5 years of age. More severe joint pain and early 
joint immobility arose in late childhood and were initially most severe in her neck and 
spine. 
Although radiographs at 9 years of age showed mild platyspondyly, anterior 
vertebral wedging and mild, generalized epiphyseal abnormalities, she carried a diagnosis 
of juvenile rheumatoid arthritis throughout childhood. She developed kyphoscoliosis in 
adolescence and had extension osteotomies of both femora at age 13 years due to 
worsening hip flexion contractures.  
She was first evaluated through the Midwest Regional Bone Dysplasia Clinics at 
age 22 years (Fig. 1a-c). Between childhood and her first assessment, joint pain 
progressively worsened, with greatest severity in her elbows, hips, knees and hands. 
Progressive joint stiffness and joint prominence developed, particularly in her hands. She 
had an adult height of ~150 cm, generalized truncal stiffness, severe neck stiffness, 
normal craniofacial features, and limited mouth opening. Shoulder abduction and 
elevation as well as elbow extension, pronation and supination were limited. Legs 
showed hip flexion contractures, only 15° of rotation, no abduction or adduction, minimal 
active hip flexion, mild knee flexion contractures, and ankle stiffness. Her stance was a 
“Z” posture (Fig. 1a-b) with absent heel strike, knee flexion, and hip flexion. Spine 
radiographs showed platyspondyly and anterior wedging (Fig. 1c). 
Over the ensuing ten years, her stiffness and pain worsened, requiring bilateral hip 




progressive thoracolumbar kyphosis and presented acutely at age 35 years with 
progressive numbness to the level of the umbilicus and leg weakness. MRI showed 
severe spinal stenosis and multilevel myelomalacia. She had laminectomy (T8-L1 and 
L4-L5) and spinal fusion, which improved her symptoms. Today, she is 38 years old and 
remains ambulatory.   
She was initially diagnosed with PPRD and included in the cohort of Hurvitz et al. 
(1999), but had no pathogenic WISP3 variants, which was confirmed by subsequent 
testing (Supp. Materials and Methods). A diagnosis of Czech dysplasia was also 
considered but rejected due to the absence of structural abnormalities of the toes or 
metatarsals. 
Concerns arose in the proband’s daughter (Table 1) during childhood. She was 
born at 36 weeks gestation with a weight of 2840 g and length of 48 cm. When first 
assessed at 3 
7
/12 years of age, her mother was concerned about a mild waddling gait, but 
examination was normal. By 5 years of age, she had progressive knee valgus, internal 
tibial torsion, mild limitation of ankle dorsiflexion, and poor heel-toe transition, but was 
otherwise normal. Between 7 and 8 ½ years of age, neck stiffness, minimal limitation of 
elbow supination, and minimal wrist stiffness were evident, as were confounding features 
caused by an unrelated subtrochanteric femur fracture.  
By age 11 ½ years, she had developed worsening neck stiffness; pain in her neck, 
hips, and knees; increased waddling; and decreased walking endurance. She had 
decreased mobility in her neck, elbows, wrists, hips, knees, and ankles. Proximal 
interphalangeal hand joints were prominent, and feet were normal except for incidental 
mild hallux valgus. Height was 135.4 cm (5
th 




kyphosis developed, mild scoliosis progressed, and joint stiffness and pain worsened, 
particularly in her hips. She is now a young adult and attends college. Joint immobility, 
particularly of the hips and knees, has continued to progress.  She has severe pain with 
ambulation and can only walk for short distances with crutches. Both hip replacement 
and spinal fusion surgeries are anticipated.   
Radiographs at 5 and 8 years of age were normal. By 12 years of age, her spine 
showed mild to moderate generalized platyspondyly, mild anterior wedging, loss of 
anterior substance and mild excess concavity of the vertebral bodies, and a lumbar 
scoliosis (Fig. 1d). There was mild, generalized joint space narrowing and metaphyseal 
irregularity (distal radii, distal ulnae, and distal femora; Fig. 1e-g), and phalangeal 
metaphyses of the hands were mildly prominent (Fig. 1g). Femoral heads were flattened 
and irregular, and femoral necks were short (Fig. 1e). The left femur was deformed 
secondary to previous injury. 
The proband of Family 2 (Table 1) is a Korean boy who presented at age 6 years 
because of awkward gait and running difficulty. He was the product of a normal full-term 
pregnancy of unaffected, non-consanguineous parents and born with a weight of 3.7 kg. 
Motor and cognitive developments were normal, and he started to walk alone at 14 
months of age. His parents noticed his slow, waddling gait and inability to run at 2-3 
years of age. He was examined by a pediatric neurologist but not found to have 
neurologic or muscle disease. His height was 118.3 cm (z=+0.6, 73th centile), and weight 
18.4 kg. His older brother and sister were unaffected. At age 8 
1
/2 years, he had an 
awkward gait and complained of difficulty squatting. He could run only slowly, and 




posture with hips and knees flexed. He showed a wide-based gait with smooth heel-toe 
progression. The knees showed 20° flexion contractures. The hips and elbows showed 
mild limitation of motion. His height was 131.5 cm (z=+0.45, 67
th
 centile) and arm span 
was 137 cm.  
At 9 
4
/12 years of age, his knee and hip joint pain worsened, precluding sports 
activities. He had a stiff gait with hip abduction. The hip joints showed 15° flexion 
contractures, and further flexion was painful and limited to 100°. Nonsteroidal anti-
inflammatories and diverse physical treatments lessened his joint pain. By 10 
1
/2 years of 
age, he could walk only with assistance due to joint pain and limb muscle weakness from 
prolonged disuse. Bearing weight on his legs resulted in hip, knee, and ankle pain. 
Motion at the hip joint was painful, with flexion contractures of 20° and flexion limited 
to 120°. The knee joint showed 20° flexion contractures.  
His initial hip radiographs at 4 years of age (Fig. 1h) showed irregular contour of 
the femoral capital epiphyses, shallow acetabulum, and wide femoral neck with mild 
coxa valga. Skeletal survey at age 8 
1
/2 years (Fig. 1i-m) revealed generalized 
platyspondyly with wedged vertebral bodies at the thoracolumbar junction. His pelvis 
showed mild capital femoral epiphyseal dysplasia, coxa valga, and small, elongated ilia. 
Hand radiographs showed no distinct metaphyseal widening of the phalanges or 
metacarpals. Feet lateral radiographs showed large os trigonum bilaterally, and 
accentuated pes cavus. We prioritized a diagnosis of SED, Stanescu type and also 
included a broad category of unclassified spondyloepiphyseal dysplasias, possibly 




apparent spondyloepiphyseal dysplasia with coxa valga, and absent metaphyseal 
widening of the phalanges, there was no initial suspicion of PPRD.  
Results 
After multiple assessments failed to detect WISP3 variants in Family 1, we 
performed WES on the proband, her unaffected mother, and her affected daughter. WES 
analysis and filtering in Family 1 (Supp. Materials and Methods) yielded 56 heterozygous 
variants, including a novel COL2A1 variant (p.Gly207Arg). Sanger sequencing 
confirmed that this variant was present in the 2 affected individuals and absent in the 
unaffected mother of the proband (Supp. Figure S1), but we were unable to confirm de 
novo occurrence in the proband since paternal DNA was unavailable. In the proband of 
Family 2, we directly evaluated COL2A1 for sequence and copy number variants because 
we suspected a type II collagenopathy (Supp. Materials and Methods). We detected the 
same heterozygous variant in the proband by full Sanger sequencing of COL2A1 (Supp. 
Table S1) and confirmed de novo occurrence by Sanger sequencing of the mutation site 
in his unaffected parents (Supp. Figure S2). Functional prediction software indicates that 
the variant occurs at a conserved residue and is predicted to be damaging (Supp. 
Materials and Methods). This variant was submitted to a COL2A1 locus-specific database 
at http://databases.lovd.nl/shared/variants/COL2A1, DB-ID COL2A1_000405, in three 






Interestingly, the clinical and radiological findings manifest somewhat differently 
between affected individuals in Families 1 and 2, although they share the same variant. 
The proband of Family 2 exhibited normal height until late childhood, and the proximal 
femora were broad and elongated with coxa valga. The proband of Family 2 also lacked 
enlarged phalangeal epimetaphyses of the hands, which is one of the hallmarks of PPRD 
and was prominent in Family 1. 
 COL2A1 encodes the alpha-1 chain of type II collagen, the primary collagen in 
articular cartilage. Many bone dysplasias are type II collagenopathies (MIM 120140), 
ranging from lethal to very mild and including Czech dysplasia. Although the individuals 
described here share many phenotypic features and the autosomal dominant mode of 
inheritance of Czech dysplasia, they lack major hallmarks including metatarsal 
shortening, which is thought to be uniformly characteristic of Czech dysplasia (Table 1). 
In addition, a single heterozygous COL2A1 variant (p.Arg275Cys) has been ascribed to 
Czech dysplasia in all published cases (MIM 609162), while the individuals described 
here are heterozygous for a p.Gly207Arg variant.  
Although there are few reports of Stanescu dysplasia, all describe a chondrocytic 
phenotype of PAS-positive, amylase-resistant cytoplasmic inclusions (Stanescu et al., 
1984; Nishimura et al., 1998). Since we did not have access to chondrocytes from our 
patients, we were unable to test for this feature. However, given the phenotypic overlap 
with our cases, it is likely that Stanescu dysplasia is also a type II collagenopathy, and 




worthwhile to investigate the possibility of COL2A1 mutation in other cases with this 
phenotype.  
Rukavina et al. (2014) implicated a c.611G>T, p.Gly204Val COL2A1 variant in a 
case of early-onset progressive osteoarthritis with mild spondyloepiphyseal dysplasia 
(Table 1; Rukavina et al., 2014). This patient shares many clinical features of the patients 
described here, suggesting similar consequences of the p.Gly204Val and p.Gly207Arg 
COL2A1 variants. 
Previous connections have been made between WISP3 and type II collagen.  
Overexpression of wild-type WISP3, but not PPRD variants, increases type II collagen in 
human chondrocytes (Sen, Cheng, Goldring, Lotz, & Carson, 2004; M. Wang et al., 
2013).  WISP3 normally co-localizes with type II collagen in the midzone region of 
chondrocytes, but WISP3 localization is disrupted by PPRD variants (Sen et al., 2004). 
Type II collagen secretion into the extracellular matrix also decreases in human 
chondrocytes transfected with mutant as compared to wild-type WISP3 (M. Wang et al., 
2013) We hypothesize that the WISP3 variants found in PPRD and the COL2A1 variant 
described here both decrease type II collagen, potentially disrupting the extracellular 
matrix and common downstream signaling pathways (Barber, Esteban-Pretel, Marín, & 
Timoneda, 2014).  
These individuals heterozygous for the p.Gly207Arg COL2A1 variant have a 
phenotype overlapping PPRD, SED, Stanescu type, and Czech dysplasia, although the 
third is clinically distinguishable by metatarsal shortening. The individuals described here 




We initially matched the common variant in these families at an academic 
conference. The team working with the proband of Family 2 described the variant in an 
abstract, which was subsequently recognized by the group following Family 1. While this 
story highlights the power of case matching, the probability that such matches will be 
made is enhanced by tools such as GeneMatcher (Sobreira, Schiettecatte, Boehm, Valle, 
& Hamosh, 2015). Based on our experience, we strongly support wider collaboration and 
data sharing, particularly for researchers and clinicians following rare disorders. 
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Chapter 2 Figures 
 
Figure 1. Clinical features of patients. a-c: Proband of Family 1 at 23 years.  Note 
marked joint contractures resulting in Z posture. c: Lateral spine radiograph shows 
platyspondyly and irregular degenerative changes. d-g: Radiographs of the daughter of 
the proband of Family 1 at 12 years. d: Mild anterior wedging and platyspondyly of 
lateral spine. e: Hip and pelvic features include flattened and irregular femoral heads, 
short femoral necks, and deformed shaft of the left femur secondary to prior trauma. f: 
Knee radiograph shows joint space narrowing and metaphyseal irregularity. g: Note 
metaphyseal prominence and joint space narrowing at distal radius and distal ulna. h-m: 
Radiographs of the proband of Family 2 at 4 years (h) and 8 years (i-m). h: Note 
irregularity and mild flattening at articular surfaces of capital femoral epiphyses. 
Acetabulum is flat, and femoral necks are broad with mild coxa valga. i: Capital femoral 
epiphyses show mild flattening and dysplastic trabeculation. Femoral necks are broad and 




acetabulum shows deepening with irregularity of its contour. j: Note moderate spinal 
platyspondyly with anterior wedging and irregularity of the endplates. k: Knee joints  
show mild flaring of the distal femora and proximal tibiae. Epiphyses are normal. l-m: 






 Family 1 Family 2 Rukavina et 
al. [2014] 






Mode of Inheritance Autosomal 
dominant 







Family Origin U.S.A. Korea Unknown Multiethnic Multiethnic Multiethnic 
Major Clinical Features       







- - - +
*
 -** - 
Hearing Loss - - - +/- +/-*** - 
Joint Pain + + + + + + 
Progressive Joint 
Immobility 
+ + + + + + 
Joint Replacement 
Surgery Needed 
+ Not yet + + + + 

















+ ? + + + + 
Metaphyseal 
Enlargement, Hands 
+ ? + +/- + + 
Metatarsal Shortening - - - +* - - 
Mutated Gene COL2A1 COL2A1 COL2A1 COL2A1 Unknown WISP3 
Genetic Variant**** c.619G>A 







N/A Allelic Heterogeneity [Hurvitz 
et al., 1999; Delague et al., 
2005; Zhou et al., 2007; Yue et 
al., 2009; Temiz et al., 2011; 
Dalal et al., 2012; Garcia 
Segarra et al., 2012; Sun et al., 
2012] 








N/A Allelic Heterogeneity (See 
references above) 
SIFT/ PolyPhen-2 Scores 0/1 0/1 0/0.999 0/0.999 N/A N/A 





*Although the patients described by Burrage et al. [2013] did not have disproportionate shortening of the 3rd and 4th toes, they did have radiologic evidence of 
generalized shortening of the metatarsals. 




 toes and 2
nd




 toe shortening 
observed in Czech dysplasia.   
***The original proband described by Stanescu et al. (1984) had sensorineural hearing loss. 




Chapter 2 Supplement 
Variant Detection in Family 1 
WISP3 was initially investigated in the proband of Family 1 by Hurvitz et al. 
(1999). Subsequent clinical molecular analysis (courtesy of James Hyland, Connective 
Tissue Gene Tests) failed to demonstrate pathogenic WISP3 variants in either the proband 
or her daughter. All five exons of WISP3 were PCR-amplified and sequenced using the 
ABI 3730 sequencer, and WISP3 was analyzed for copy number variants using a CTGT 
high-density targeted array.  Both these methods failed to detect any pathogenic sequence 
or copy number variants in WISP3.   
Next, we performed whole exome sequencing on the proband, her unaffected 
mother, and her affected daughter at the Baylor-Hopkins Center for Mendelian Genomics.  
The patients were counseled on the possible outcomes of whole exome sequencing and 
signed a consent form approved by the Johns Hopkins University School of Medicine 
Institutional Review Board.  To capture the CCDS coding regions and adjacent intronic 
sequences, we used the Agilent SureSelect Human All Exon V4 51Mb capture kit to 
obtain paired-end 100 bp reads on the Illumina HiSeq2500 platform.  Reads were aligned 
to the reference genome (NCBI human genome assembly build 37; Ensembl core 
database release 50_361 (Hubbard et al., 2009)) using the Burrows‐Wheeler Alignment 
(BWA) tool (H. Li & Durbin, 2009), and single nucleotide variants (SNVs) and small 
insertion‐deletions (indels) were identified using SAMtools (H. Li et al., 2009). We 
performed local realignment and base call quality recalibration using GATK2.3.9 
(DePristo et al., 2011; McKenna et al., 2010).  We then selected for variants with a 






, and end distance bias below 10
-4
.  Using a presumed autosomal dominant 
inheritance model, we prioritized variants using the Analysis Tool of PhenoDB (Hamosh 
et al., 2013).  We selected for rare heterozygous variants with MAF<0.01 in the 1000 
Genomes Project (Build 20130502; 1000 Genomes Project Consortium et al., 2012); 
dbSNP builds 126, 129, and 131 (Sherry et al., 2001); Exome Variant Server (release 
ESP6500SI-V2); and our in-house control database (CIDRVar 51Mb), and 
nonsynonymous exonic or splicing SNVs and indels which were present in affected 
individuals but absent in unaffected individual.   
Variant Detection in Family 2 
We directly sequenced the COL2A1 gene in the proband of Family 2 because his 
radiological findings suggested a spondyloepiphyseal dysplasia.  Genomic DNA was 
extracted from peripheral blood leukocytes. The COL2A1 gene was screened by direct 
Sanger sequencing of all coding exons and their flanking regions (Supp. Table S1). 
Multiplex ligation-dependent probe amplification (MLPA) analysis was performed to 
screen gross gene deletions and duplications involving this gene using the SALSA P214 
COL2A1 (MRC-Holland, Amsterdam, Netherlands).  Upon detection of the variant of 
interest, Sanger sequencing of the mutation site was performed on both unaffected 
parents of the proband to confirm co-segregation of the variant with the phenotype (Supp. 
Figure S2). 
Prediction of Variant Pathogenicity 
The novel COL2A1 variant (RefSeq transcript NM_001844.4: c.619G>A, 
p.Gly207Arg) was assessed for putative conservation and functionality using a variety of 




Evolutionary Rate Profiling score, GERP++ version) of 4.81 (Davydov et al., 2010); a 
SIFT score of 0 (SIFT v. 1.03, score range 0-1.0, with scores ≤0.05 predicted damaging; 
Kumar, Henikoff, & Ng, 2009); and a PolyPhen-2 score of 1 (score range 0 (benign) to 
1.0 (probably damaging), PolyPhen-2 v.2.2.2; Adzhubei et al., 2010).  These scores 







Supp. Figure 1. Sanger validation of COL2A1 variant in Family 1.  Sanger 




(p.Gly207Arg, RefSeq transcript NM_001844.4) with the phenotype in Family 1.  Whole 
exome sequencing originally detected this variant in the proband and her affected 
daughter, but not in her unaffected mother.  Primers were designed for amplification and 
subsequent Sanger sequencing of a 357 bp fragment encompassing the COL2A1 variant.   
Results confirm co-segregation of the COL2A1 variant with the phenotype in Family 1 
(the variant is present in the proband and her affected daughter, but absent in her 
unaffected mother).  Primer sequences were as follows: 
Forward  CACCAGGATTGCCTTGAAAT 
Reverse  TAGAGTGTTGCGTGGGGAGT 
 
 
Supp. Figure 2. Sequence analysis of COL2A1 exon 9 in Family 2. The proband was 
heterozygous for the missense variant c.619G>A (p.Gly207Arg, RefSeq transcript 
NM_001844.4).  This missense variant was not detected in his unaffected parents, 





Supp. Table 1. Primers used for Sanger sequencing of COL2A1 gene in the proband 
of Family 2. 
Exon Forward primer sequence Reverse primer sequence 
1 AGCGTGACTCCCAGAGAGG GGTGAACTTCTGCGTGTCCT 
2 CCCAGCCTACATTCTTCAGC GTGGCCTTTCCTTTCTACCC 
3-6 AGAGGGGTTCAGTGGAGTCA AGGTGACCAGGCCCTTAAAC 
7 AAAAGCAATGCTGCTTGACC GCCCTTAGCACCACAGTCTC 
8 ACTTTCCAGGCATCAGTGGT CTGGACAGCAGCCATGTTTA 
9-10 CTGTCCAGGAGAAAGCAAGG GGGGGCTGTTAGGACAGAGT 
11 CCACCAGGGACTCTGTCCTA ACTTGCCAGCACAGTCACAG 
12 GGTGAGGACAGAGGAGCTTG TCCCTCATGAGAGCCTGAGT 
13-14 AGGGGTGGTCTGGGTTTTAC CAGGATGTAGGGCTGGTGTT 
15 GCATTGTCCCTCACAGGACT ACAAGCACACCTTGCTCCTT 
16 TCTGAGGCATCCTGGCTAGT CACACTGGGGGTGAATTCTT 
17 AGCCAGACTCCGTCTCAAAA CCTCCCCCTTTCCAGTAGAC 
18 CTGAAGCCAGGCAAAGTTTC ACTGCGAGTGTCTGGCTTTT 
19 TGGGTGCATGTGCATAATTT GGCATAGGTGCTGTCCATTT 
20-21 ATGTCCCTGAAATGGACAGC AAGAGAGGCAGGTCCTCACA 
22 CTCTTTCCCATGCTCTCCTG AGGGAAGTGAGAGGGGCTAA 
23 CAGTTGCCAAGGCTACTTCC CATGTCAGTCTGGTGGTTGG 
24-26 ACAGCTACTGCTCCCCAGAA GCCTACCATCTACCCCCTGT 
27 AAGCTCAGCGGTGTCTTGTT CTTCTGTTCAGGGGCCATAA 
28 TTATGGCCCCTGAACAGAAG TGACCAATGGCAAACAGAAG 
29 GTACCGTGGAGGTCTGGAAA CTTCCTGCACCACTCAGACA 
30-31 TGTCTGAGTGGTGCAGGAAG GACATGGGTCCAGGACATTC 
32-33 AGCCTCCACAGATGACACAA GACAGCACCTCTCCCTGAAC 
34 TGCATCCTGTAGGGGTCTTC TTCATCACCAGGTGCCATAA 
35-36 ACATCCTTTCCCCTGTTCCT ACAAGACAGAACCGCCTTTG 
37 ATGGGCTGCACAGTAACACA CTCTCCTCCCACCCTAGACC 
38-39 CCATCATGTGTTCAGGGTGA CTACCAACATGGGGGTGTTC 
40 CACAAGTCTCCTGTGGCAGA  TCCACAGTCAGCACTTCAGG 
41 GTTCAGCTCCCTGAAGTGCT GGTCCCCATGATCAGTTAGC 
42 AGGTAGAGAAGCCCCCAGAG TGAGAGAGGAGAGGCAGGAG 
43-44 TCTGAGCTCACAGAGCATGG CAAGTTTCCCTCCTCCTTCC 
45-46 GAAGGAGGAGGGAAACTTGG CGTCAGAGAAAAGCCAGGAC 




49 GACAGCTTGGGATCACCCTA AGCGAGAGGCTGATTCATGT 
50 ATGAATCAGCCTCTCGCTGT CAGGCTGATGCCCTAAAAGA 
51 CTGACTCCTTCCCTGCTGTC CCCAGCTCTGCCCTGTACTA 
52 CCTCATCCCTTGTCCCTGTA CAGCAGGGAGCTAGTTGGAC 
53 GCAGAGATGGCTCCTCAAAC TCATGCCTCTGATGATCCTG 
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Introduction 
 Incidental findings in whole exome and whole genome sequencing are variants of 
known or possible pathology identified in genes unrelated to the initial reason for which 
sequencing tests were ordered.  As large-scale sequencing is increasingly used in a 
clinical setting, standardizing procedures for identifying, classifying, and reporting 
variants is of great importance.  In 2013, the American College of Medical Genetics and 
Genomics (ACMG) released a recommendation suggesting that known pathogenic or 
expected pathogenic constitutional variants detected in 56 genes representing 24 
conditions with well-known guidelines for prevention or treatment should be reported to 




these recommendations, the Clinical Sequencing Exploratory Research (CSER) 
Consortium and Electronic Medical Records and Genomics (eMERGE) Network 
followed by releasing a set of guidelines for the return of incidental findings within 
genomics research studies (Jarvik et al., 2014).  These guidelines recommended that 
medically actionable incidental variants be returned to willing research participants, but 
exempted researchers from an obligation to search for these variants. 
Although incidental variants are unexpected, when variant pathogenicity is certain, 
the information enables patients to make proactive decisions about their health and 
inform their physician.  However, some variants are of uncertain significance, or initial 
interpretation of variant pathogenicity may be subject to change (Bell et al., 2011). 
Reporting these variants of uncertain significance (VUS) to patients may lead to 
misinterpretation of the results, produce unnecessary anxiety, and diminish confidence in 
genetic test results in general.  Thus, transmittal of these results requires accurate and 
thoughtful genetic counseling and careful evaluation of available sources of variant 
classification to maximize benefits and minimize harm to patients.   
At the Baylor-Hopkins Center for Mendelian Genomics (BHCMG, 
http://mendeliangenomics.org), we utilize whole exome sequencing to detect variants 
responsible for Mendelian disorders with unknown molecular bases.  Since we sequence 
across the exome, we not only capture variants that are responsible for the patient 
phenotype, but also incidental variants which may predispose and/or cause other 
unrelated disorders.  Returning meaningful results to research participants through their 




findings detected at the research level and knowing which of these should be returned to 
patients is of special interest.   
 Although the ACMG guidelines for reporting incidental findings are geared toward a 
clinical setting, they provide a well-defined, targeted set of genes from among the many 
interrogated in research sequencing.  Thus, our results on this set may inform policies for 
handling incidental findings.  Here we examine the implementation of the ACMG clinical 
guidelines within a research setting by assessing the spectrum of rare, functional variation 
in the 56 genes in whole exome sequences of 232 individuals in 89 families sequenced at 
the Baylor-Hopkins Center for Mendelian Genomics for a variety of Mendelian disorders 
with unknown molecular bases, some of which have features that overlap with the 
disorders covered by the ACMG list.  We then assessed variant interpretation by 
evaluating classification and reportability according to available databases and 
approaches taken by others in the literature.   
Materials and Methods 
All research participants were counseled on the possible outcomes of whole 
exome sequencing and signed a consent form approved by the Johns Hopkins University 
School of Medicine Institutional Review Board.  Participants chose whether they would 
like to receive information regarding primary or incidental variants found in the course of 
this study and were given the opportunity to opt out or in at any time.   
Whole exome sequences from 232 individuals in 89 families sequenced at Johns 




indels in the 56 reportable genes from the ACMG guidelines using the analysis feature of 
the web-based system PhenoDB (Hamosh et al., 2013).  
Briefly, whole exome sequencing was done on the Illumina HiSeq2000 platform 
(Illumina, Inc., San Diego, CA) using paired-end 75 or 100 bp reads.  51 Mb of genomic 
DNA comprised of CCDS exons and adjacent intron sequences were captured with 
Agilent SureSelect Human All Exon V4 51Mb Kit (Agilent Technologies, Santa Clara, 
CA).   FASTQ files were aligned to the reference genome (GRCh37; Ensembl core 
database release 50_361; Hubbard et al., 2009) with the Burrows‐Wheeler Alignment 
(BWA 0.5.10) tool (H. Li & Durbin, 2009) resulting in SAM/BAM output (H. Li et al., 
2009).  PCR duplicates were flagged with Picard (http://picard.sourceforge.net).
 
 Local 
realignment around indels, base call quality score recalibration and reduced reads BAMs 
were performed with GATK 2.3-9 (McKenna et al., 2010).  Multi-sample SNV and indel 
calling was performed with GATK’s UnifiedGenotyper on the reduced reads BAM files. 
Variant sites were filtered with GATK’s Variant Quality Score Recalibration best 
practices (DePristo et al., 2011), and heterozygous genotypes were excluded if they did 
not have at least 5 alternate allele reads.  Sequencing coverage of the 56 genes is listed in 
Supplementary Table S1. 
We selected for nonsynonymous SNVs, exonic indels, and splice junction variants 
(2 most 5’ and 3’ intronic bases) in each of the 56 reportable genes.  Nonsynonymous 
SNVs and exonic variants were defined by RefSeq Gene coordinates (Pruitt, Tatusova, & 
Maglott, 2004).  Next, we filtered these variants on the basis of their minor allele 
frequencies (MAF), with exclusion of variants with MAF ≥ 0.01 in the 1000 Genomes 




Variant Server (http://evs.gs.washington.edu/EVS/), dbSNP build 137 (Sherry et al., 
2001), and our in-house control database (CIDRVar 51Mb), which includes data from 50 
individuals sequenced in-house with the Agilent51Mb exome capture kit (Agilent 
Technologies, Santa Clara, CA). 
Next, we analyzed the variants for prior classification in the Human Gene 
Mutation Database (HGMD; Stenson et al., 2003), ClinVar (Landrum et al., 2014), and 
the Emory Genetics Laboratory Variant Classification Catalog (Bean, Tinker, da Silva, & 
Hegde, 2013).  We then defined the burden of variants in each individual sequenced and 
the mutability of each gene (number of rare functional variants/gene and number of rare 
functional variants/kb of coding region), and the classification and reportability of each 
variant.   
Results 
In the 232 exomes, we identified 249 distinct variants in the 56 gene ACMG 
target set, some of which were seen in more than one individual, for a total of 391 
variants.  A total of 124 variants were shared between family members, and 18 variants 
were shared between unrelated individuals.  There was an average of 1.69 variants per 
individual, with a range of 0-7 variants per individual.  There were only 45 people 
(19.4%) with no variants, and in the 232 exomes we found at least one variant in 45 of 
the 56 genes (80.4%; Supplementary Table S1). 
We then stratified these 249 distinct variants by type (Table 1).  Most variants 




(1.6%), 2 splice variants (0.8%), 3 frameshifting indels (1.2%), 5 nonframeshifting indels 
(2.0%), and 4 nonsense variants (1.6%).  
Next, we checked the classification of these variants in three databases: HGMD, 
ClinVar, and Emory.  Of the 249 distinct variants identified, 126 (50.6%) were classified 
by at least one of the three databases: 54/126 (42.8%) were represented solely in HGMD; 
44/126 (34.9%) were in HGMD and ClinVar; 23/126 (18.3%) were in ClinVar alone; 
2/126 (1.6%) were in Emory alone; and another 3/126 (2.4%) were in all three databases 
(Figure 1).   
In total, 101/249 variants (40.5%) were listed in HGMD (94 missense SNVs 
(93.1%), 2 nonsynonymous exonic/splicing variants (2.0%), 2 splicing variants (2.0%), 1 
nonsense SNV (1.0%), and 2 nonframeshifting indels (2.0%)).  More importantly, 
HGMD classified 74 (72.8%) as disease-causing mutations (DM), 24 (24.3%) as possible 
disease-causing mutations (DM?), 1 (1.0%) as a functional polymorphism (FP), and 2 
(1.9%) as disease-associated polymorphisms (DP) reported to be in significant 
association with disease (p<0.05) along with some evidence of functionality.   
Of the 148 variants not classified by HGMD, 23 variants in 13 genes were 
described by ClinVar and 2 variants in 2 genes were listed in Emory.  This left a total of 
123/249 variants (49.4%) that were not present in any database (Figure 1).  
The classification of variants within these three databases was often discordant.  
Of the 101 variants represented in HGMD, 48 were also in ClinVar.  Three of these 48 
variants were also in Emory. Almost half of these shared variants (22/48 variants, or 




Next, we examined the effects of gene size and evolutionary constraint on the 
number of functional variants within each gene, in a manner similar to that described by 
Petrovski et al. (Petrovski, Wang, Heinzen, Allen, & Goldstein, 2013).  Some genes 
consistently had greater variation than others.  For instance, BRCA2, APOB, CACNA1S, 
and DSP had the greatest number of variants/gene (Supplementary Table S1). Since 
increased coding length increases the target size for mutation, larger genes are expected 
to have a higher number of variants than smaller genes.  To explore this possibility, we 
analyzed the number of variants per gene against the size (kb) of the consensus coding 
sequence (CCDS) of the gene.  We found that the number of variants per gene generally 
increased with the size of coding sequence, and the number of variants showed a 62.8% 
correlation with the size of the consensus coding sequence (Figure 2).   
We also found that some genes (e.g. RB1, PMS2, and MLH1) consistently have a 
lower variant density (variants/kb coding sequence) than others (e.g. MYBPC3, TMEM43, 
and MYL3) (Supplementary Table S1).  The values of variant density range from 0.4 
variants per kb in RB1 to 3.4 variants per kb in MYL3. As described by others, a possible 
explanation for this variation in mutational burden despite correction for coding sequence 
length is varying degrees of evolutionary constraint (Petrovski et al., 2013).  Certain 
genes are under a higher degree of purifying selection than others, and this is likely 
reflected by less variation per unit coding length.  
Determining Reportable Variants 
To determine which variants should be reported to our research participants, we 
adopted a stringent set of measures outlined in a recent paper (Dorschner et al., 2013).  




including comparison between variant minor allele frequencies and incidences of the 
corresponding disorders; familial segregation data; observation in unrelated affected 
individuals; de novo events in a trio; and protein truncation in disorders caused by 
haploinsufficiency.  If a variant is classified as pathogenic or likely pathogenic by these 
criteria, it is considered reportable back to the patient.   
We applied these criteria to all 391 variants in the 56 ACMG genes detected in 
232 exomes.  In total, we found 2 pathogenic variants (in MSH2 and MYLK) and 3 likely 
pathogenic variants (in LMNA, MYBPC3, and MUTYH), as shown in Table 2.  One of 
these genes, MUTYH, is responsible for autosomal recessive conditions (MYH-associated 
polyposis; adenomas, multiple colorectal, FAP type 2; colorectal adenomatous polyposis, 
autosomal recessive, with pilomatricomas; MIM 608456 and 132600).  Since current 
ACMG guidelines recommend reporting only individuals with homozygous variants in 
MUTYH (Green et al., 2013), we would not report this heterozygous variant to the patient.  
Since the patients in our cohort underwent whole exome sequencing to explain a variety 
of potential Mendelian disorders, some of which have overlapping features with the 
disorders covered by the ACMG list, we recognized that our cohort may have an 
enrichment of reportable variants as compared to the general population.  Indeed, two 
patients, one with a likely pathogenic variant in LMNA and one with a likely pathogenic 
variant in MYBPC3, had clinical phenotypes which included dilated cardiomyopathy, so 
we did not count these two cases toward our final number of incidental variants.  In total, 
this means that 2/232 individuals, or 0.86% of our sample, had a reportable incidental 






In June of 2014, Jarvik et al. released recommendations for dealing with 
incidental variants in the research arena.  The authors suggested that researchers be 
exempted from an obligation to search for variants outside the intended scope of their 
study, but that actionable variants be reported to research participants when discovered 
(Jarvik et al., 2014). The present study describes the workflow for identification and 
classification of incidental findings in the Johns Hopkins component of the Baylor-
Hopkins Center for Mendelian Genomics based on the ACMG recommendations and on 
the classification criteria from Dorschner et al. (Dorschner et al., 2013). 
In 232 exomes, we identified a total of 391 rare (MAF < 1%) variants in the 56 
ACMG genes (1.69 variants per individual), 249 of which were distinct variants. Most of 
these variants were missense (231/249, or 92.8%), and half were not classified by any of 
the three databases (HGMD, ClinVar, and Emory) that we used to assess variant 
classification (123/249 variants, or 49.4%).  Since these novel variants were not 
represented in the variant databases, they could not be utilized for comparative analyses 
of classifications among the three databases.  
Next we used the criteria described by Dorschner et al. to classify the 391 total 
variants identified in 232 exomes and found that 2/232 individuals, or 0.86% of our 
sample, had an incidental reportable variant in one of the 56 ACMG genes.  Overall, this 
analysis was quite time-consuming, but we were able to automate parts of it such as 
filtering variants whose frequency was higher than that predicted by the frequency of 
their associated disorders.  This step reduced the number of distinct variants from 249 




original variants required further assessment.  We were also able to automate selection of 
variants in the HGMD, ClinVar, and Emory classification databases using our web-based 
system, PhenoDB (Hamosh et al., 2013).  Although we did not consider the 
classifications from these databases in support of variant pathogenicity or reportability, 
the databases provided useful citations from the literature and clinical observations for 
some variants.  This information reduced the time required for manual review.  Protein 
truncation was automatically predicted, but required manual inspection to confirm that 
protein truncation is an established cause of the disorder associated with the respective 
gene.  The most time-consuming part of the process was reviewing the literature for each 
variant to count familial segregations, de novo events, and singleton reports.  This step 
required additional expertise regarding diagnoses of the disorders on the ACMG list.  
Moreover, evaluation of cases in the literature was somewhat subjective. 
Several other studies have analyzed reportable incidental findings within whole-
exome or whole-genome sequences to-date.  The study by Dorschner et al., whose criteria 
we adopted for our analysis of reportable variants, found that 14/1000 individuals 
sequenced (1.4%) had a pathogenic or likely pathogenic reportable variant in one of the 
52 ACMG genes responsible for adult-onset conditions (Dorschner et al., 2013).  
Johnston et al. found that 8/572 (1.39%) individuals sequenced through the ClinSeq 
project had a reportable variant in one of 37 cancer genes; 23 of these are on the ACMG 
list (Johnston et al., 2012). These numbers are similar to ours and to those in the original 
ACMG guidelines, which anticipated that 1% of individuals sequenced would have a 




Another recent report by Lawrence et al. detected 27/543 individuals (~5%) 
sequenced through the NIH Undiagnosed Diseases Program with an incidental variant in 
one of the 56 ACMG genes (Lawrence et al., 2014).  Their method differed from ours in 
a few ways which may have contributed to the discrepancy in frequency of incidental 
findings.  For instance, they used reported functional studies as evidence of pathogenicity; 
required fewer informative meioses to count familial co-segregation events with disease; 
did not apply minor allele frequency cutoffs; and used designations in variant 
classification databases as evidence in support of variant pathogenicity.  In addition, a 
few individuals in their cohort had a phenotype related to the reported incidental finding, 
and some incidental variants were repeated due to familial transmission (Li Wang et al., 
2010).  These differences in methodology may have contributed to the discrepancies in 
numbers of reportable incidental findings. 
During this process we recognized that identifying and classifying the multitude 
of incidental variants that arise from next-generation sequencing is a time-consuming and 
subjective process dependent on the particular methodologies of each individual 
investigator. We confirmed this last observation when we found that almost half (22/48, 
or 45.8%) of the 101 variants represented in at least 2 databases were given discordant 
classifications between them. We compared these database classifications to our variant 
classifications from the Dorschner et al. method (Dorschner et al., 2013) and found that 
variant classifications from the ClinVar and Emory databases, but not the HGMD 
database, were generally consistent with our variant classifications (Supplemental Table 
S2).  This is likely because HGMD aims to provide a comprehensive listing of all 




2003) that may not be accurate, consistent, up-to-date, or sufficient to provide support of 
variant pathogenicity.  For these reasons, HGMD is generally less conservative than the 
other databases. 
The abundance of rare and novel missense variants in our cohort made accurate 
assessment of variant pathogenicity more challenging, since all novel and many rare 
missense variants must initially be classified as variants of unknown significance (VUS).   
For many rare variants, familial segregation data or de novo events in a trio were not 
available or sufficient to define variants as pathogenic or likely pathogenic.   
When we observed de novo variants in a trio or co-segregation of a variant with 
disease, family information could be used as evidence supporting pathogenicity and 
reportability.  Although failure of a variant to segregate might be considered evidence 
against pathogenicity, we did not use this information in our pathogenicity evaluations, 
since many disorders on the ACMG list are adult-onset and could be late to manifest in 
unaffected family members.  Family sequence data is also useful for determining the 
phase of multiple heterozygous variants in a single gene, and thus can be used for finding 
compound heterozygous variants.  When individuals rather than families are sequenced, 
it may be more difficult to classify variants as pathogenic or likely pathogenic since these 
sources of information are not available.  However, support for pathogenicity can be 
obtained in other ways, such as literature searches.  Thus, family information is helpful 
but not necessary for determining variant pathogenicity in most cases. 
We found that prediction is even more difficult in genes that are subject to more 




information was not available for most variants, 152/249 distinct variants (61.0%) were 
classified as VUS. 
Some variants had been previously described in the dbSNP, EVS, and/or 1000 
Genomes databases, and of 249 distinct variants, 126 (50.6%) were classified by at least 
one of the three databases used to assess variant classification (HGMD, ClinVar, and/or 
Emory).  The available classifications in these cases were helpful but not always clear, 
mainly due to discrepancies among bioinformatic prediction databases or functional 
studies; low numbers of unrelated affected individuals with the same variant; 
misreporting of variant pathogenicity in the literature or classification databases; or 
occurrence of variants in large or highly mutable genes.  These inconsistencies all point 
to the need for a single, centralized database and methodology for variant classification. 
Our study has several limitations.  First of all, many individuals in our cohort 
were ascertained for various Mendelian disorders.  Because of this, two of the reportable 
findings could not be considered incidental, in that they may actually have contributed to 
the phenotype of the patients.  In addition, our cohort was relatively small, and 73% of 
individuals self-identified with European descent.  Moreover, we may have missed some 
variants due to low coverage in some regions of the 56 ACMG genes.  Another limitation 
was the minor allele frequency cut-offs that we employed.  For our early comparisons of 
variant classification between databases, we used a 1% MAF cut-off, which may be too 
high for some disorders and necessitate more time for manual review of variants.  On the 
other hand, our later assessments of variant reportability used more stringent minor allele 
frequency cut-offs based on expected disease prevalences.  This increased stringency may 




method we used to find reportable variants fails to consider functional studies.  Because 
of this, we may have excluded some variants which have been functionally characterized 
as pathogenic or included variants which show milder or less conclusive functional 
consequences. 
An alternative sequencing method like whole-genome sequencing would increase 
detection of incidental findings as well as VUS, owing to the increased coverage of this 
method and the challenge of interpreting noncoding variants.  Whole-genome sequencing 
will uncover structural variants and copy-number variants as well.  However, the ACMG 
recommendations currently apply only to SNVs and indels, so this additional variation—
some of which may be significant—would not be considered under the current guidelines 
(Green et al., 2013). 
Based on this experience, we suggest that clinicians and researchers interested in 
returning incidental variants found by next-generation sequencing adopt a uniform, well-
defined set of criteria for variant classification.  Here we applied the ACMG 
recommendations and the classification criteria defined by Dorschner et al. (2013), but 
we suggest that the addition of bioinformatic prediction tools, genic intolerance scores, 
and functional studies to the criteria would make variant classification more complete.  
We also expect that research and clinical laboratories performing next-generation 
sequencing will soon be more engaged in submitting variants to manually curated 
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Chapter 3 Figures 






Figure 2. The number of variants per gene plotted against the size (kb) of the 
consensus coding sequence (CCDS) of the gene.   
 
Chapter 3 Tables 
Table 1. Classification of the 249 variants by mutation type. 
Variant Type Number of Variants 
Missense SNV 231 
Nonframeshifting indel 5 
Nonsense 4 
Exonic/Splicing 4 














Criteria met Classification Reportable? Incidental? Patient  
ancestry 





MAF < cutoff 
In 3 unrelated affected  
individuals (Astejada et al., 2007; 
Cowan, Li, Gonzalez-Quintana, 
Morales, & Hershberger, 2010; 




Yes No European 





MAF < cutoff 
Protein truncation in disease 
caused by haploinsufficiency (S. 
R. Payne & Kemp, 2005) 
Pathogenic Yes Yes Admixed  
African/  
European 
MUTYH 1 45798269T>C NM_001048173.1: 
c.583A>G,  
p.Ile195Val 
MAF < cutoff 
Segregation in one affected family
 
(Morak, Massdorf, Sykora, 













MYBPC3 11 47356628G>C NM_000256.3: 
c.2870C>G, 
p.Thr957Ser 
MAF < cutoff 
 
In 3 unrelated affected individuals 
(Ehlermann et al., 2008; Olivotto 





Yes No European 





MAF < cutoff 
Protein truncation in disease 
caused by haploinsufficiency (Li 
Wang et al., 2010)
 
 





Chapter 3 Supplement 
 
Supplementary Table 1. Variation found in 56 ACMG genes in whole exome sequences of 232 individuals. 
Whole exome sequences from 232 individuals representing 89 families were analyzed for rare (MAF<0.01), nonsynonymous and 
splice variants and indels in the 56 genes on the ACMG list (Green et al., 2013).  We identified 249 distinct variants, some of which 
were seen in more than one individual.  The number and density of variants (number of variants/kb coding sequence) varied by gene.  










% of UCSC-defined gene (coding exons) with > 15 reads 
BRCA2 21 2.05 119.19 100 
APOB 18 1.31 145.84 99.3 
CACNA1S 17 3.02 77.21 100 
DSP 16 1.86 139.22 99.5 
RYR1 15 0.99 70.55 95.9 
MYBPC3 12 3.14 73.39 96 
RYR2 12 0.81 97.18 100 
BRCA1 11 1.97 128.26 98.6 
MYH11 9 1.52 86.16 99.3 
MYH7 9 1.55 89.83 99.3 
TSC2 8 1.47 68.63 99.2 
DSG2 7 2.09 117.28 98.6 
FBN1 7 0.81 82.62 100 
MSH6 7 1.71 140.95 100 
PKP2 7 2.65 61.38 85.9 




APC 5 0.59 138.56 100 
LDLR 5 1.94 97.36 100 
MUTYH 5 3.05 100.4 100 
COL3A1 4 0.91 60.42 97.6 
KCNH2 4 1.15 57.09 93.4 
MSH2 4 1.43 69.57 96.8 
TMEM43 4 3.33 69.6 100 
DSC2 3 1.11 88.23 99.2 
LMNA 3 1.50 65.56 93.8 
SCN5A 3 0.50 94.67 100 
TSC1 3 0.86 79.03 100 
KCNQ1 2 0.98 51.29 90.8 
MEN1 2 1.08 88.65 97.5 
MYL3 2 3.40 69.42 100 
PCSK9 2 0.96 54.74 97.2 
RET 2 0.60 73.72 98.8 
TGFBR1 2 1.32 93.89 93.5 
GLA 1 0.78 80.29 100 
MLH1 1 0.44 83.88 99.9 
NF2 1 0.56 69.81 99.8 
PMS2 1 0.39 111.39 100 
RB1 1 0.36 78.21 99.5 
SDHAF2 1 2.00 89.02 100 
SDHB 1 1.19 66.82 100 
TGFBR2 1 0.59 89.8 100 
TNNT2 1 1.17 74.71 99.9 
TP53 1 0.85 75.77 100 
VHL 1 1.56 83.57 100 
WT1 1 0.64 56.33 100 
ACTA2 0 N/A 76.42 100 
ACTC1 0 N/A 90.69 99.1 
MYL2 0 N/A 98.89 100 




PTEN 0 N/A 115.28 100 
SDHC 0 N/A 45.33 92.4 
SDHD 0 N/A 27.01 71.8 
SMAD3 0 N/A 72.32 98.9 
STK11 0 N/A 60.34 97.4 
TNNI3 0 N/A 72.82 100 

















Supplementary Table 2.  Discordant classification of variants among databases. 
Three databases (HGMD (Stenson et al., 2003), ClinVar (Landrum et al., 2014), and Emory (Bean et al., 2013)) were examined for 
classification of the 249 distinct variants identified in 232 individuals’ whole exome sequences.  Of 48 variants which were classified 
by more than one database, 22 variants were given discordant classifications between databases.  We then compared these database 
classifications to our variant classifications derived from the Dorschner et al. method
 
(Dorschner et al., 2013) and found that variant 
classifications given by the ClinVar and Emory databases but not HGMD were generally consistent with our variant classifications.  
These results show the lack of consensus for variant classification methodologies among currently available databases.  
(Abbreviations:  DM-Disease-causing (pathological) mutation, based on information from the literature; VUS-Variant of Uncertain 






























DM No known 
pathogenicity 












17 41245900T>G c.1648A>C, 
p.Asn550His 
DM No known 
pathogenicity 






et al., 2006) 
BRCA1 
(NM_007294.3) 
17 41223048A>G c.4883T>C, 
p.Met1628Thr 
DM Probably not 
pathogenic 









13 32907129T>C c.1514T>C,  
p.Ile505Thr 
DM Probably not 
pathogenic 
N/A VUS MAF < prevalence 
of disorder 
 
In < 3 unrelated 
affected individuals 
(Cavallone et al., 
2010; Edwards, 
Kote-Jarai, 
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N/A VUS MAF < prevalence 
of disorder 
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affected individuals 
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N/A Likely benign 
VUS 
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of disorder 
 













DM Variant of 
unknown 
significance 
N/A VUS MAF < prevalence 
of disorder 
 
In < 3 unrelated 
affected individuals 








DM Variant of 
unknown 
significance 
N/A Likely benign 
VUS 









DM Probably not 
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DM Probably not 
pathogenic 
N/A Likely benign 
VUS 









DM Variant of 
unknown 
significance 
N/A VUS MAF < prevalence 
of disorder 
 
In < 3 unrelated 
affected individuals 
(Al-Jassar et al., 
2011) 















DM Variant of 
unknown 
significance 
N/A VUS MAF < prevalence 
of disorder 
 
In < 3 unrelated 
affected individuals 
(Landrum et al., 








DM Probably not 
pathogenic 
N/A VUS MAF < prevalence 
of disorder 
 
In < 3 unrelated 
affected individuals 
(Jääskeläinen et al., 
2002; Moolman-
Smook, De Lange, 














MAF < prevalence 
of disorder 
 
In 3 unrelated 
affected individuals 
(Ehlermann et al., 
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Chapter 4. Mutations in PCYT1A, encoding a key regulator of 
phosphatidylcholine metabolism, cause spondylometaphyseal 
dysplasia with cone-rod dystrophy 
Chapter 4 is reprinted from the final accepted journal article:  
Hoover-Fong J, Sobreira N, Jurgens J, Modaff P, Blout C, Moser A, Kim O-H, Cho T-J, 
Cho SY, Kim SJ, Jin D-K, Kitoh H, Park W-Y, Ling H, Hetrick KN, Doheny KF, Valle 
D, Pauli RM. (2014). Mutations in PCYT1A, encoding a key regulator of 
phosphatidylcholine metabolism, cause spondylometaphyseal dysplasia with cone-rod 
dystrophy. Am J Hum Genet. 94(1): 105-12. 
Julie Jurgens’s Contributions: Targeted sequencing of PCYT1A in some families; Sanger 
validation and segregation analysis of variants; restriction digest validation of variant in 
one family; writing portions of manuscript and assistance with submission process; figure 
and table preparation; assistance with revision and reformatting. 
 
Introduction 
 The spondylometaphyseal dysplasias (SMDs) are a group of about a dozen rare 
disorders characterized by short stature, irregular, flat vertebrae and metaphyseal 
abnormalities.  Aside from spondylometaphyseal dysplasia Kozlowski type (MIM 
184252) caused by mutations in TRPV4 (MIM 605427) and spondyloenchondrodysplasia 
(MIM 607944) due to mutations in ACP5 (MIM 171640), the genetic etiologies of SMDs 
are unknown (Warman et al., 2011). Two of these unexplained SMDs have 
ophthalmologic manifestations: SMD with cone-rod dystrophy (SMD-CRD [MIM 
608940]) and axial SMD with retinal degeneration (MIM 602271).  
Delineated clinically a decade ago, SMD-CRD is a presumed autosomal recessive 
disorder with postnatal growth deficiency leading to profound short stature; rhizomelia 




progressive metaphyseal irregularity and cupping with shortened tubular bones; and early 
onset, progressive visual impairment associated with a pigmentary maculopathy and 
electroretinographic evidence of cone-rod dysfunction (Kitoh et al., 2011; Sousa, Russell-
Eggitt, Hall, Hall, & Hennekam, 2008; Turell, Morrison, & Traboulsi, 2010; Walters et 
al., 2004). In contrast to retinitis pigmentosa, the CRDs have early involvement of cone 
photoreceptors (Hamel, 2007).  
Here, we report loss of function mutations in PCYT1A (MIM 123695) as the cause 
of SMD-CRD. PCYT1A encodes CTP:phosphocholine cytidylyltransferase (CCTα; 
Fagone & Jackowski, 2013; Kent, 2005), a key enzyme in the CDP-choline or Kennedy 
pathway for de novo phosphatidylcholine biosynthesis.  
Subjects and Methods 
 We used whole exome and targeted sequencing of members of 6 unrelated families 
with 8 individuals with SMD-CRD (Figure 1). Three families were submitted to the 
Baylor-Hopkins Center for Mendelian Genomics (BHCMG) through the online 
submission portal PhenoDB (Hamosh et al., 2013) and, to confirm our observations in the 
first 3 families, we recruited 3 additional families for targeted candidate gene sequencing. 
The clinical features of these individuals are summarized in Table 1 and briefly reviewed 
here. Six of the subjects have been described in previous publications (Kitoh et al., 2011; 
Walters et al., 2004). 
Subject 1 (BH2265_1; Family 1; Figure 2A) was reported when she was 20 y old 
(Walters et al., 2004). Now age 29 y, she has done well with continued linear growth to 
an adult height of 93.9 cm (-10.7 SD) and modest progression of limitation of range of 




(BH2283_1; Family 2, Figure 2E), originally described at age 11 y, is now 20 y old with 
a current adult height of 139 cm (-5.3 SD) and some progression of joint stiffening. His 
visual function declined during his second decade and he now requires low vision aids. 
Subject 3 (BH2233_1; Family3) is a previously unreported 61-year-old female who was 
first seen at age 51. Although her skeletal phenotype is similar to that of the others 
described here, she had a late-onset retinal phenotype (Figure 2B). Radiographs from 
childhood were reported to show platyspondyly and metaphyseal changes; adult 
radiographs show hypoplasia of the posterior vertebral bodies but no anterior vertebral 
protrusions.  Adult height (measured at age 54 y) is 108.3 cm (-8.4 SD). Visual 
symptoms were not apparent until middle age. An ERG at age 43 y (performed because 
she had a brother with visual impairment) was said to be normal. By age 51 y, however, 
her ERG showed evidence of cone-rod dysfunction and her current vision is limited 
(Table 1). At age 54 y, her examination showed short stature, rhizomelic limb shortening, 
brachydactyly, stiffness of large joints and internal tibial torsion. Her family history 
includes an affected brother, who died at age 45 y and was known to have short stature 
and a confirmed CRD. Her parents may be distantly related. Subjects 4-6 were reported 
by Walters et al.
2
 as their cases 3-5, and have not been formally assessed since that time 
but provided updated information regarding visual function (Table 1, Figure 2C and D). 
Subject 7 (Family 5) was previously described (Kitoh et al., 2011). Subject 8 (Family 6) 
is a 23 m old previously unreported Korean male referred for evaluation of growth failure 
and disproportionate shortening of the limbs. He has an increased antero-posterior 
thoracic diameter, rhizomelic shortening of his extremities and bilateral bowing of the 




hearing impairment was noted at his first examination. Linear growth was impaired (by 
North American standards): at 23 m he was 68.4 cm (-5.2 SD), and at 48 m 71.2 cm (-7.4 
SD). From age 2 y he had frequent pneumonias with episodes of desaturation and O2 
dependency thought to be due to chest wall deformity. He had a waddling gait due to 
coxa vara deformity. Radiographs at 23 m showed short, bowed long bones with flared, 
cupped, and spurred metaphyses, and the adjacent epiphyses were large and rounded. In 
the hands and feet, the metaphyses of the short tubular bones had mild cupping, widening, 
and flaring, and the diaphyses were short. The vertebral bodies were ovoid, mildly 
flattened, with anterior projections. These radiographic abnormalities were more severe at 
age 45 m. Mild scoliosis developed. Although no visual impairment was noted at age 23 
m by age 45 m fundus examination showed hypopigmented macular atrophy in both eyes 
with markedly decreased photopic and moderately decreased scotopic ERGs.  
For our molecular studies, we isolated genomic DNA from fresh whole blood 
using the Gentra Puregene Kit (Qiagen Sciences, Germantown, MD). Subjects 1, 2 and 3 
were genotyped on Illumina’s ExomeChip1.1 GWAS array. This allows us to estimate 
inbreeding coefficient based on the observed and expected homozygous genotypes at 
genome wide level among 199 unrelated Caucasian samples (defined by PCA) after LD 
pruning (PLINK). The inbreeding coefficient was 0.1535, -0.007 and 0.035 for subjects 1, 
2 and 3 respectively, suggesting subject 1 (BH2265_1) is the product of an unrecognized 
consanguineous union. Although subject 3 is also homozygous for p.A99V mutation, B 
allele frequency plot showed multiple loss-of-heterozygosity segments across genome for 
subject 1 but not subject 3. This result suggests that homozygosity for p.A99V in subject 





For WES, we captured the CCDS exonic regions and flanking intronic regions 
totaling ~51Mb using the Agilent SureSelect Human All Exon V4 51Mb Kit and 
performed paired end 100 bp reads on subjects 1-3 using the Illumina HiSeq2000 
platform. We aligned each read to the reference genome (NCBI human genome assembly 
build 37; Ensembl core database release 50_361; Hubbard et al., 2009) using the 
Burrows‐Wheeler Alignment (BWA) tool (H. Li & Durbin, 2009) and identified single 
nucleotide variants (SNVs) and small insertion‐deletions (indels) using SAMtools (H. Li 
et al., 2009). We also performed local realignment and base call quality recalibration 
using GATK (DePristo et al., 2011; McKenna et al., 2010). We identified potentially 
causal variants using standard filtering criteria: SNV and indel minimal depth of 8X, root 
mean square mapping quality of 25, strand bias p-value below 10
-4
, end distance bias 
below 10
-4
, and filtering out SNVs within 3bp of an indel and indels within 10bp of each 
other; followed by the use of the Analysis Tool of PhenoDB (Hamosh et al., 2013) to 
design the prioritization strategy
 
(Sobreira, personal communication).  We prioritized rare 
functional variants (missense, nonsense, splice site variants and indels) that were 
homozygous or compound heterozygous in each of the 3 subjects and excluded variants 
with a MAF > 0.01 in dbSNP 126, 129, and 131 or in the Exome Variant Server (release 
ESP6500SI-V2) or 1000 Genomes Project (1000 Genomes Project Consortium et al., 
2012). We also excluded all variants found in our in-house controls (CIDRVar 51Mb). 
We generated a homozygous and a compound heterozygous variant list for each subject 
and merged them to identify genes that were mutated in both alleles in all three subjects. 




direct Sanger sequencing to validate candidate causative variants, determine their 
segregation within families, and to sequence PCYT1A in subjects 4-8. All the variants 
described here were based on the Refgene transcript NM_005017.2 and NCBI human 
genome assembly build 37 (Table 1). 
Results 
Analysis of WES data in subjects 1-3 identified 2 genes containing candidate 
causal mutations in all 3 subjects: TTN (MIM 188840) and PCYT1A. TTN is a large gene 
(313 exons) expressed primarily in skeletal and cardiac muscle (Y. Zhang et al., 2007). 
TTN variants are found frequently in controls (Lopes et al., 2013) and have been 
implicated as causative in various cardiac and skeletal myopathies (Carmignac et al., 
2007; Gerull et al., 2002; Hackman et al., 2002; D. S. Herman et al., 2012; Itoh-Satoh et 
al., 2002; Lange et al., 2005; Lopes et al., 2013; Satoh et al., 1999), but not in individuals 
with retinal or skeletal dysplasia phenotypes. For these reasons, we removed TTN from 
consideration, leaving PCYT1A as the only gene with rare variants in both alleles in all 3 
subjects. Subjects 1 and 3 are homozygous for the PCYT1A missense variant p.Ala99Val 
(c.296C>T) in exon 5 and subject 2 is a compound heterozygote for p.Ala99Val and 
p.Pro150Ala (c.448C>G) in exon 6 of PCYT1A. These variants are not present in 
the >6,000 individuals in the Exome Variant Server nor in the 1092 individuals whose 
sequence is currently available from the 1000 Genomes. Direct Sanger sequencing of 
PCR amplified products confirmed appropriate Mendelian segregation of these variants 
in available family members (Figure 1). Based on these results, we used PCR and 
bidirectional Sanger sequencing to interrogate all PCYT1A exons and flanking intronic 




heterozygotes for rare PCYT1A variants.  
 Thus, in total, we identified 8 rare PCYT1A variants (1 nonsense, 1 frame shifting 
indel, and 6 missense variants) present either in the homozygous or compound 
heterozygous state in 8 individuals with SMD-CRD in 6 families from around the world 
(Table 1). The missense mutations all change highly conserved residues, including one, 
Ala99, that is altered by two different variants (p.Ala99Val, p.Ala99Thr) and all are 
predicted to be damaging by SIFT (Kumar et al., 2009) and either probably damaging or 
possibly damaging by PolyPhen-2 (Table 1; Adzhubei et al., 2010). The c.296C>T 
variant producing the p.Ala99Val change occurs at a CpG dinucleotide on the reverse 
strand, while, the mutation in the same codon producing p.Ala99Thr (c.295G>A) in 
family 4 does not involve a CpG dinucleotide.  To determine if the three unrelated 
subjects with the p.Ala99Val change have a shared or recurrent mutation, we utilized the 
SNP genotyping data to analyze IBD sharing and runs of homozygosity to show that, as 
predicted by the different geographical origins of the 3 families, the p.Ala99Val variants 
in families 1-3 are on different haplotypes indicating that  recurrent CpG mutations are 
responsible. 
Discussion 
Located at 3q29, PCYT1A (Figure 3) contains 10 exon, is ubiquitously expressed 
and encodes CCTα, an amphitropic enzyme that catalyzes the synthesis of CDP-choline 
from phosphocholine and CTP. The CCTα reaction is the rate-limiting step in the major 
pathway for phosphatidylcholine synthesis (Figure 4; Fagone & Jackowski, 2013; Kent, 
2005). In mammals, phosphatidylcholine can also be synthesized from 




methyltransferase (PEMT) but the expression of the enzyme is limited to liver (Figure 4; 
Fagone & Jackowski, 2013; Glunde, Bhujwalla, & Ronen, 2011; Kent, 2005). 
Phosphatidylcholine is the predominant phospholipid in eukaryotic membranes (Fagone 
& Jackowski, 2013; Kent, 2005). Consistent with the importance of CCTα in 
phosphatidylcholine synthesis, a mouse knockout of Pcyt1a is an early embryonic lethal 
in the homozygous state (L. Wang, Magdaleno, Tabas, & Jackowski, 2005). An X-linked 
PCYT1A paralog, PCYT1B (MIM 604926), encodes three isoforms CCTβ1, CCTβ2 and 
CCTβ3 with activities similar to CCTα but whose expression is limited to the central 




 The 367 residue CCTα has 4 domains: a 73 residue N-terminal domain 
containing the nuclear localizing signal, a 163 residue catalytic domain, a 64 residue 
membrane-binding M domain, and a C-terminal 67 residue unordered domain with 
multiple residues that undergo phosphorylation (Figure 3; Ding et al., 2012; J. Lee, 
Johnson, Ding, Paetzel, & Cornell, 2009). CCTα is found as an inactive homodimer in 
the nucleoplasm where, in response to lipid signaling, it binds to the nuclear membrane 
through interactions mediated by the amphipathic M domain and becomes catalytically 
active (Fagone & Jackowski, 2013; J. Lee et al., 2009).
 
 The sequence and domain 
structure of CCTα is highly conserved across phylogeny and the crystal structure of the 
catalytic domain of rat CCTα, which has 100% sequence identity with human CCTα, has 
been solved (J. Lee et al., 2009). 
The PCYT1A missense alleles identified in the subjects with SMD-CRD all 




phylogeny. All mutations change residues in the catalytic domain of CCTα: Ala99 
(altered in subjects 1, 2, 3, 4, 5 and 6) is adjacent to Gln98 which is directly involved in 
binding CDP; Pro150 (altered in proband 2) is adjacent to Trp151 which is also directly 
involved in binding choline; Phe191 (altered in proband 8) is located 3 residues N-
terminal to Thr194 which plays a role in coordinating CDP.  The p.Glu129Lys and 
p.Arg223Ser substitutions alter residues that are linearly more distant from those that 
interact directly with substrates (J. Lee et al., 2009). The nonsense mutation, c.847C>T, 
occurs in the penultimate exon 9, 50 bp from the 3’ end of the exon and possibly results 
in nonsense mediated RNA decay of the mutant transcript. The 1 bp indel allele in subject 
7 (c.990delC) changes the frame and creates a longer transcript with 102 extra amino 
acids (p.Ser331Profs*140). We conclude that these variants, on the basis of the their 
extremely low frequency, the high conservation of the involved residues and predicted 
deleterious consequences for enzymatic activity, their occurrence in homozygosity or 
compound heterozygosity in multiple unrelated affected individuals in six families and 
their segregation fitting an autosomal recessive model, are PCYT1A loss of function 
alleles responsible for the SMD-CRD phenotype. 
 Like the deficiency of choline kinase B caused by mutations in CHKB (MIM 612395) 
responsible for muscular dystrophy, congenital megaconial type (MIM 602541; 
Mitsuhashi et al., 2011), SMD-CRD seems to be another inborn error in the 
phosphatidylcholine synthetic pathway. The central importance of this lipid in membrane 
biology suggests that complete loss of function of this pathway would result in 
embryonic lethality, as observed in mice homozygous for Pcyt1a null alleles (L. Wang et 




their skeletal and retinal involvement. One possible explanation is that despite the 
predicted severe functional consequences of the mutations we describe, there remains 
some residual CCTα function. This may be augmented by activity of the CCTβ isozymes 
and by synthesis of phosphatidylcholine from phosphatidylethanolamine by the PEMT 
catalyzed reaction in the liver (Fagone & Jackowski, 2013). The activities of the CCTβ 
isozymes and PEMT were increased in cells derived from conditional Pcyt1a knockout 
mice (Jacobs, Devlin, Tabas, & Vance, 2004; D. Zhang et al., 2000).  These possibilities 
should be explored as they may suggest therapeutic strategies that could be effective, 
especially in younger SMD-CRD individuals.   
Our results suggest a connection between bone and retinal lipid metabolism that 
would explain the sensitivity of these two tissues to deficiency of CCTα and impaired 
phosphatidylcholine synthesis.  Photoreceptors have an especially high demand on 
membrane biosynthesis due to the daily shedding of outer segment discs (LaVail, 1976).
   
Thus, it is not surprising that these cells might be especially susceptible to defects in the 
biosynthetic pathway for the most abundant membrane phospholipid. Indeed, 
photoreceptor degeneration in the rd11 mouse has been shown to be due to loss of 
function mutations in the gene encoding lysophosphatidylcholine acyltransferase 1 
(Lpcat1), a phospholipid remodeling enzyme (Bridges et al., 2010; Friedman et al., 2010).
 
  
Interestingly, bone formation is abnormal in certain Mendelian disorders caused by 
mutations in genes encoding proteins involved in fatty acid metabolism, including 
rhizomelic chondrodysplasia punctata (MIM 215100; Braverman et al., 2002) and the 
Conradi-Hunermann form of chondrodysplasia punctata (MIM 302960; G. E. Herman et 




formation and homeostasis. 
Among our families there was no obvious genotype-phenotype correlation 
apparent from evaluation of the 6 affected individuals in 4 families with mutations 
altering codon Ala99. Subjects 1 and 3, both homozygous for c.296C>T, p.Ala99Val, 
have strikingly dissimilar age at onset of visual phenotype, of clinical characteristics and 
of radiologic features. This broad range of phenotypic severity in individuals with the 
same mutations at the disease gene locus suggests that variation in other components of 
the phosphatidylcholine pathways and/or environmental variables may have a strong 
influence on phenotypic manifestations and severity. Understanding these variables may 
lead to improved management of individuals with SMD-CRD. Interestingly, one of the 
individuals described here, subject 8, has had frequent pneumonias and has required 
supplemental oxygen from age 2 y. We speculate that this might relate to the high 
demand for phosphatidylcholine in surfactant biosynthesis by the alveolar type II cells 
(Agassandian & Mallampalli, 2013; Goss, Hunt, & Postle, 2013). These cells are known 
to express PCYT1A at high levels and phosphatidylcholine is the major phospholipid 
component of surfactant (Agassandian & Mallampalli, 2013; Goss et al., 2013; Ridsdale, 
Tseu, Wang, & Post, 2001). A conditional, epithelial cell-specific Pcyt1a knockout 
mouse had severe respiratory failure at birth and reduced levels of surfactant (Tian, Zhou, 
Rehg, & Jackowski, 2007).  Although only one of the individuals described here has had 
this problem, the potential biological connections suggest that additional studies of 
pulmonary function and surfactant status in proband 8 and possibly other cases of SMD-
CRD is warranted.      




associated with a skeletal dysplasia. By contrast, there are several examples of RP 
associated with bony abnormalities including some for which the responsible gene is yet 
to be identified (Ehara, Kim, Maisawa, Takasago, & Nishimura, 1997; Isidor, Le Merrer, 
Ramos, Baron, & David, 2009). CRD and RP may be part of the same phenotypic 
spectrum of retinal degeneration. Mutations in certain genes have been reported to cause 
either phenotype (Cremers et al., 1998; Yang et al., 2008). For this reason, we suggest 
that PCYT1A should be assessed in any individual with CRD or RP associated with any 
form of spondylometaphyseal dysplasia or spondyloepiphyseal dysplasia, including in 
particular, individuals with the axial SMD with retinal degeneration phenotype (MIM 
602271). 
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Chapter 4 Figures 
Figure 1. Pedigrees of families 1-6 showing the segregation of PCYT1A mutant 
alleles. Alleles with the wild type genotype indicated by “+”. Samples were not available 






Figure 2. Clinical and radiographic features of SMD-CRD. A – General physical 
phenotype (Subject 1 at age 16 y 5 m); B – Fundus photograph showing pigmentary 
maculopathy (Subject 3 at age 61 y); C – Spine and pelvis radiograph demonstrating 
platyspondyly, characteristic pelvic configuration and proximal femoral metaphyseal 
changes (Subject 6 at 3 y 8 m of age); D – Pelvis and femurs showing the marked 
metaphyseal changes that are typical (Subject 4 at age 11 y 1 m); E – Knee radiographs, 
similarly showing the marked metaphyseal changes that are typical in this diagnosis 






Figure 3. PCYT1A structure and domain organization of CCTα. PCYT1A is located at 
3q29 and includes 10 exons (gray rectangles) as shown on the top line of the diagram. 
The thin rectangles encode the 5’ and 3’ UTR sequences. The right angle arrow denotes 
the start of the open reading frame and the asterisk indicates the location of the stop 
codon. The genomic coordinates on chromosome 3 are shown above. Below in color is a 
diagram of CCTα showing the domain structure with the diagonal dashed lines indicating 
the exons that contribute to each domain. The N-terminal domain (N) is in light blue with 
a dark blue rectangle indicating the position of the nuclear localization signal. The 
catalytic domain (C) is in pink. The amphitrophic membrane-binding domain (M) is in 
green and the C-terminal phosphorylated domain (P) is in purple. The numbers below 
indicate the residues at the boundaries of the domains. The mutations and their locations 






Figure 4. Pathways of phosphatidylcholine biosynthesis. In this figure, enzymes are 
indicated by numbers as defined below. Choline (Cho) is transported from the 
extracellular fluid across the plasma membrane by Na
+
-dependent, ATP-requiring choline 
transporter-like proteins (1). Free intracellular choline is phosphorylated by choline 
kinase (2) to produce phosphocholine (P-Cho).  The latter is converted to cytidine-
diphosphate choline (CDP-Cho) in a reaction catalyzed by phosphocholine 
cytidylyltransferase (CCTα, 3). CDP-choline is esterified with diacylglycerol (DAG) to 
phosphatidylcholine (PtdCho) in reactions catalyzed either by cholinephosphotransferase 
(4) or choline/ethanolaminephosphotransferase (5).  PtdCho is converted to lyso-
phosphatidylcholine (Lyso-PtdCho) by phospholipase A (6) which, in turn, is converted 
back to PtdCho, in a reaction catalyzed by acylglycerophosphate acyltransferase (7).   In 
mammals, a second pathway of PtdCho synthesis is limited to liver, where PtdCho is 
synthesized from phosphatidylethanolamine (Ptd-Eth) in a series of methylation reactions 
catalyzed by phosphatidylethanolamine N-methyltransferase (8) with S-
adenosylmethionine (SAM) as the methyl donor. The red rectangle indicates the position 
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Chapter 5:  
Loss of function in PCYT1A has broad and cell-type specific 
consequences on lipid metabolism, chondrocyte differentiation, 
and lipid droplet formation 
Jurgens J, Chen S, Sobreira N, Robbins S, Franca A, Dastgheyb R, Khuder S, Hoover-
Fong J, Woods C, Collins F, Christodoulou J, Yamamoto G, Baratela W, Nguyen S, 
Haughey N, Cornell R, Valle D 
 
Julie Jurgens’s Contributions: Conceptualization and execution of all experimental 
procedures, data analysis and interpretation for all figures and tables, preparation of 
manuscript and all figures and tables 
Introduction 
Spondylometaphyseal dysplasia with cone-rod dystrophy (SMD-CRD) is a rare, 
autosomal recessive disorder of the skeleton and the retina. Clinical characteristics 
include progressive, early-onset photoreceptor degeneration—particularly in the 
macula—as well as short stature, bowing of the long bones, metaphyseal flaring, 
rhizomelic shortening, platyspondyly, and scoliosis. Using whole exome sequencing and 
Sanger sequencing, Hoover-Fong et al. (2014) and Yamamoto et al. (2014) identified 
homozygous or compound heterozygous variants in PCYT1A as the cause of SMD-CRD 
(Hoover-Fong et al., 2014; Yamamoto et al., 2014).  These variants ranged from missense 
(RefSeq NM_005017.2: c.296C>T, p.Ala99Val; c.295G>A, p.Ala99Thr; c.385G>A, 
p.Glu129Lys; c.448C>G, p.Pro150Ala; c.571T>C, p.Phe191Leu; and c.669G>C, 
p.Arg223Ser) to nonsense variants (c.847C>T, p.Arg283Ter) or frameshifting indels 
(c.990delC, p.Ser331Profs*?; c.968dupG, p.Ser323Argfs*38; c.996delC, 




two additional missense alleles in PCYT1A in patients with SMD-CRD (c.341G>C, 
p.Ser114Thr and c.718T>C, p.Tyr240His; Jurgens et al., personal communication). 
Interestingly, compound heterozygous PCYT1A variants were also detected in two 
unrelated probands with congenital lipodystrophy and fatty liver disease (F. Payne et al., 
2014).  These patients had no ascertainable retinal or skeletal findings, suggesting a 
distinct pathophysiological mechanism. Both patients shared an in-frame deletion variant 
(c.838_840delCTC, p.Glu280del) in trans to a second variant in the other allele 
(c.424G>A, p.Val142Met or c.996delC, p.Ser333Leufs*164, respectively). Testa et al. 
recently reported a third class of patients with biallelic PCYT1A variants and retinal 
degeneration, but no accompanying skeletal dysplasia or lipodystrophy (Testa et al., 
2017). Both probands shared the same PCYT1A missense variant (c.277G>A, p.Ala93Thr) 
in trans to an inactivating variant in the second allele (c.897+1G>A or c.847C>T, 
p.Arg283Ter, respectively). 
PCYT1A encodes CTP:phosphocholine cytidylyltransferase α (CCTα), which 
catalyzes the rate-limiting step in de novo synthesis of phosphatidylcholine (PC) by the 
Kennedy pathway. PCYT1A is expressed ubiquitously in mice and in humans, and PC is 
the predominant membrane phospholipid in mammalian cells (R. B. Cornell & Ridgway, 
2015; Karim, Jackson, & Jackowski, 2003; Keenan & Morré, 1970; L. Wang, Magdaleno, 
Tabas, & Jackowski, 2005; GTEx project release v7). Complete loss of Pcyt1a 




mice experience embryonic lethality 
(L. Wang et al., 2005), and MT-58 CHO cell lines with a 95% loss-of-function point 




on this evidence, PC production by the Kennedy pathway appears to be essential for life, 
at least in these model systems.   
Though most PC is produced by the CCTα-dependent Kennedy pathway in 
mammalian cells, there are other compensatory pathways for PC production in mammals 
(R. B. Cornell & Ridgway, 2015; Jackowski et al., 2004; Fig. 2). PCYT1B, a paralog of 
PCYT1A, encodes the enzyme CCTβ, which catalyzes the same Kennedy pathway 
reaction as CCTα but has limited expression in the brains and reproductive tissues of 
mice and humans (Jackowski et al., 2004; Karim et al., 2003; GTEx project v7). 
Independently of the Kennedy pathway, PC can be formed by sequential methylation of 
another phospholipid, phosphatidylethanolamine (PE), by the PEMT pathway, which 
functions primarily in liver and adipocytes (Hörl et al., 2011; Kennedy & Weiss, 1956). 
Finally, in a series of reactions known as the Lands cycle, PC can either be converted into 
lysophosphatidylcholine (LPC) through fatty acid removal catalyzed by phospholipase A2 
(PLA2), or LPC can be reacylated to form PC by lysophosphatidylcholine 
acyltransferases (LPCATs) (Lands, 1957; Vance & Vance, 2004).  Interestingly, rd11 
mice with Lpcat1 deletions have a retinal degeneration phenotype, bolstering support for 
involvement of this arm of the phospholipid metabolism pathway in retinal degeneration 
(Friedman et al., 2010).  
CCTα has a variety of functional domains which regulate its activity, conformation, 
and localization (R. B. Cornell & Ridgway, 2015). First, CCTα possesses a catalytic 
domain which is responsible for catalyzing PC production by the Kennedy pathway. In 
addition, an N-terminal nuclear localization signal localizes CCTα to the nucleus in most 




activation, CCTα undergoes a series of conformational changes mediated by a 
membrane-binding domain (M domain) and a C-terminal phosphorylation domain in 
order to bind the nuclear lamina. Membrane binding elicits catalytic activation of the 
enzyme. It is worth noting that most SMD-CRD variants are missense variants within the 
catalytic domain of the enzyme (Fig. 1), although two variants fall in the M domain 
(p.Tyr240His and p.Arg283Ter) and three frameshifting indels localize to the C-terminal 
phosphorylation domain (p.Ser331Profs*?, p.Ser323Argfs*38, and p.Ser333Leufs*?). 
CCTα has a number of interesting features from a cell biology standpoint, including its 
relationship with cellular organelles called lipid droplets (LDs). LDs form in response to 
loading with neutral lipids (e.g. oleate) in order to promote lipid storage and to protect 
against cytotoxicity (Walther, Chung, & Farese, 2017). Phospholipids such as PC are 
required for the formation of LD membranes, which encapsulate neutral lipids and 
prevent their coalescence (Krahmer et al., 2011).  Some neutral lipids activate CCTα and 
stimulate PC production; for instance, oleate facilitates the dephosphorylation and 
membrane translocation of CCTα, leading to its activation (Aitchison, Arsenault, & 
Ridgway, 2015; Cornell & Vance, 1987; Gehrig, Cornell, & Ridgway, 2008; Lagace & 
Ridgway, 2005; Pelech, Pritchard, Brindley, & Vance, 1983; Y. Wang, Macdonald, & 
Kent, 1993).  Accordingly, Drosophila, mouse, and rat cells deficient in CCTα orthologs 
accumulate fewer and larger lipid droplets as compared to their wild-type counterparts in 
response to oleate loading (Aitchison et al., 2015; Guo et al., 2008; Krahmer et al., 2011).  
Here we describe the generation and characterization of three distinct cellular model 
systems—cultured dermal fibroblasts, HEK293 cells, and ATDC5 cells—to interrogate 




fibroblasts obtained from SMD-CRD patients, we sought to understand the consequences 
of SMD-CRD variants on cellular phenotypes in an endogenous context. Next, we 
generated PCYT1A-null HEK293 cell lines in order to assess the impact of variants on 
previously described cell biology phenotypes such as lipid droplet formation.  Finally, we 
created a PCYT1A-null ATDC5 (pre-chondrocyte) cell lines, which are putatively more 
relevant to SMD-CRD pathophysiology and allowed us to measure the effects of 
PCYT1A variants on chondrocyte proliferation and differentiation. Using a combination 
of biochemical, cellular, and lipidomic approaches, we determined that SMD-CRD 
variants or complete loss of PCYT1A expression results in highly variable and cell-type 
specific phenotypic consequences. 
Materials and Methods 
Patient consent 
Our study was approved by the Johns Hopkins Medicine Institutional Review Board 
and by the IRBs of other participating institutions. We obtained informed consent from 
all responsible individuals who participated in this study. 
Cell Culture 
Primary adherent fibroblast cells were derived from skin biopsies of SMD-CRD 
patients or wild-type controls.  ATDC5 cells were a gift from Dr. Jill Fahrner of Johns 
Hopkins University (ECACC, Cat#99072806). HEK293T cells were a gift from Dr. 
Jeremy Nathans of Johns Hopkins University. CHO-K1 cells were a gift from Dr. James 
Phang of the NIH (ATCC, Cat#CCL61). All cell lines were cultured at 37° C under 5% 
CO2 and passaged using 1 x trypsin-EDTA (Gibco, 15400-054). HEK293, CHO, and 




non-essential amino acids (Gibco, 11140-050), 1% L-glutamine (Gibco, 25030-149), and 
10% fetal bovine serum (Gemini Biosciences, 100-106). For experiments using 
delipidated serum, culture medium was the same, except 10% delipidized fetal bovine 
serum (Gemini Biosciences, Cat#900-123) was substituted for regular fetal bovine serum.  
Prior to chondrocyte differentiation, ATDC5 cells were maintained in DMEM/F12 
50/50 (Corning Cellgro, 15-090-CV) with 1% L-glutamine (Gibco, 25030-149), and 5% 
fetal bovine serum (Gemini Biosciences, 100-106), and 1% penicillin-streptomycin 
(Gibco, 15140-122). Chondrocyte differentiation was induced by adding 1 x 
insulin/transferin/selenium (Corning Cellgro, 25-800-CR) to the culture medium for 21 
days.  
DNA extraction and Sanger sequencing 
DNA was extracted from blood or cell lines using the Puregene Blood Core Kit B 
(Qiagen, Cat#158467). PCYT1A exons were PCR-amplified from SMD-CRD patient 
genomic DNA with Accuprime Taq polymerase (Invitrogen, Cat#12339-016) and 
standard thermal cycling conditions using custom primer sequences. 
PCYT1A cDNA construct generation 
     RNA was extracted from PCYT1A-wild-type human fibroblasts using the RNeasy 
Mini Kit (Qiagen, Cat#74104), reverse-transcribed according to manufacturer protocol 
(SuperScriptIII One-Step RT-PCR system with Platinum Taq DNA 
Polymerase;Invitrogen, Cat# 12574-018), and cloned into the pcDNA3 mammalian 
expression vector (Invitrogen, V790-20) using primers designed to amplify full-length 
PCYT1A cDNA (based on NCBI transcript NM_005017.2) and attach restriction enzyme 




TACGTAAGCTTAGCGCCACCTCAGAAGATAA-3’, reverse primer: 5’-
CTGAGCTCGAGTTGGGGTCACAATTTGGAAT-3’). Single base-pair SMD-CRD 
missense variants were then introduced using QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent, Cat # 200521).  All plasmids were sequence-verified prior to 
use. 
Plasmid transfection 
Transfections were conducted using Lipofectamine 2000 as prescribed by 
manufacturer protocol (Invitrogen, Cat#11668-019) with ratios of 1.6 μg total plasmid 
DNA: 4 μL Lipofectamine for 12-well plate transfections, or ratios of 4.0 μg total 
plasmid DNA: 10 μL Lipofectamine for 6-well plate transfections. For lipid droplet 
rescue experiments, plasmid cDNAs harboring wild-type or SMD-CRD patient variants 
in PCYT1A were transfected into PCYT1A-null HEK293 cells and 24 hours post-
transfection, cells were incubated with 1 mM oleate medium and further processed for 
imaging, as described below. 
Protein extraction and western blotting 
Upon reaching ~80% confluency, cells were quickly washed, scraped into ice-cold 
1xPBS supplemented with protease inhibitors (Sigma-Aldrich, P8340-5ML), and 
centrifuged for 5 minutes at 1,000 x g. Cells were then resuspended in RIPA buffer (150 
mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) 
with protease inhibitors (Sigma-Aldrich, P8340-5ML), vortexed briefly, and lysed at 4° C 
with rotation and periodic low-speed vortexing. Cell debris were pelleted via 
centrifugation at 12,000 x g for 15 minutes, and the supernatant was isolated for 




BCA protein assay kit (Pierce, 23225) and diluted 40 μg of each protein with XT sample 
buffer (Bio-Rad, 1610791) and XT reducing agent (Bio-Rad, 1610792) as prescribed by 
company protocols. Samples were denatured by boiling for 5 minutes, then cooled and 
run on 4-12% Bis-Tris Criterion XT precast gels (Bio-Rad, 3450123) with XT MOPS 
Running Buffer (Bio-Rad, 1610788).  Transfer was conducted onto Immun-Blot PVDF 
membranes (Bio-Rad, 162-0177) at 4° C with 100 V for 1 hour in 1 x Tris/Glycine Buffer 
(Bio-Rad, 1610734) and 20% methanol (Fisher Scientific, A41220). Blots were blocked 
for 1 hour at room temperature in 5% nonfat dried milk in TBST (0.5% Tween-20, 137 
mM NaCl, 200 mM Tris, pH 7.5), then incubated in the appropriate primary antibodies 
(anti-β-actin antibody AC-15, ThermoFisher Scientific AM4302, 1:10,000 dilution; anti-
CCTα, Abcam, ab109263, 1:1,000 dilution) diluted in 5% nonfat dried milk in TBST at 4° 
C overnight. Membranes were washed 3 x 10 minutes in TBST, incubated for 1 hour at 
room temperature in the appropriate secondary antibodies diluted 1:10,000 in 5% nonfat 
dried milk in TBST (goat anti-rabbit IgG-HRP, Santa Cruz Biotechnology sc-2004; goat 
anti-mouse IgG-HRP, Santa Cruz Biotechnology sc-2005). Membranes were washed 3 x 
10 minutes in TBST, then incubated in ECL reagent (GE Healthcare Life Sciences, 
RPN2106) for 5 minutes and exposed to CL-X Posure Film (Thermo Scientific, 34091).  
Phosphatidylcholine incorporation assay 
To assess the effect of PCYT1A variants on the rate of phosphatidylcholine synthesis 
by the Kennedy pathway, we monitored continuous incorporation of [Methyl-
3
H]-choline 
chloride (NEN Radiochemicals, NET109001MC) into phosphatidylcholine over time as 
described previously (Kitos, Drobnies, Ng, Wen, & Cornell, 2006). Wild-type or SMD-




glutamine, and non-essential amino acids in 60 mm dishes until ~80% confluency, and 
then counted using the Beckman Coulter Particle Counter Z1. Normal growth medium 
was aspirated, and cells were incubated in serum-free medium at 37° C with 5% CO2 for 
1 hour.  We then added 5 µCi [
3
H]-methyl-choline per dish and returned to the incubator, 
or quenched immediately for our 0 minute time point. After each time point was reached, 
cells were quickly rinsed in ice-cold 1xPBS, and radiolabel uptake was quenched by 
adding 1 mL of ice-cold methanol per dish.  Cells were then placed on ice and scraped 
into prechilled glass tubes containing 1 mL chloroform, and residual cells were scraped 
with an additional 1 mL of methanol. We then added 0.75 mL H20 per tube, mixed by 
vortexing at low speed, and added 1 mL additional chloroform followed by 1 mL of H20 
per tube.  Cells were then vortexed briefly to mix, followed by centrifugation for 5 
minutes at 1000 RPM to form a biphasic mixture. The lower organic phase (containing 
lipids) was then transferred to a scintillation vial, evaporated under nitrogen gas 
(Organomation Associates, Inc., Berlin, MA, USA) and resuspended in 10 mL Insta-Gel 
Plus scintillation fluid (Perkin Elmer, 6013399), followed by counting with a Beckman 
LS6500 scintillation counter. Previous thin layer chromatography analyses have shown 
that >90% of counts in the organic phase following up to 2 hours incubation are 
attributable to phosphatidylcholine (M. N. P. Ng, Kitos, & Cornell, 2004), so counts in 
this phase were used as a proxy for radiolabeled phosphatidylcholine levels. All sample 
counts were corrected for background counts, obtained using a blank scintillation vial. 
Genome editing 
Genome editing was performed as described previously, with slight modification 




mouse PCYT1A (RefSeq NC_000003.11 or NC_000082.5, respectively) were designed 
using the CRISPR MIT portal (Hsu et al., 2013), modified into oligonucleotides for 
cloning purposes, and cloned according to the submitter’s laboratory protocol into the 
pSpCas9(BB)-2A-Puro (PX459) V2.0 plasmid (Addgene, Cat #62988), which was a gift 
from Feng Zhang’s laboratory (Ran et al., 2013). By combining two guide RNAs 
targeting the beginning and end of the genomic sequence of either human or mouse 
PCYT1A, we generated ~31 kb genomic deletions in either human (HEK293 cells) or 
mouse (ATDC5 cells) PCYT1A, effectively excising the majority of the coding sequence.  
Cells were seeded for transfection at ~2 x 10
5
 cells/well in six-well plates, grown to ~80% 
confluency, and transfected using Lipofectamine 2000 as prescribed by manufacturer 
protocol (Invitrogen, 11668-019), with equal DNA amounts of each guide RNA-encoding 
plasmid (2 μg each plasmid DNA: 10 μl Lipofectamine). Next, we treated cells with 
puromycin-containing medium at either 2 μg/mL (HEK293 cells) or 4 μg/mL (ATDC5 
cells) 24 hours post-transfection. Medium was replaced daily for 2-3 days, until cells in 
untransfected control wells died. Single cells were then isolated by serial dilution in 
puromycin-free medium, expanded into isogenic clones, subjected to DNA extraction, 
and screened for both wild-type and deletion-containing genomic DNA by PCR 
amplification.  Clones which contained the PCYT1A deletion but not wild-type genomic 
DNA were genotyped using Sanger sequencing and tested for CCTα protein levels by 
western blot analysis. 
Cell proliferation assays 
Cell proliferation was measured using the Cell Counting Kit-8 (Dojindo Molecular 




using the Beckman Coulter Particle Counter Z1, plated at 1000 cells per well in 96-well 
plates, and cultured for the respective amounts of time indicated in our growth curve. 
Growth was measured by incubating with CCK-8 solution for 3 hours, followed by 
absorbance reading at 450 nm with the Biotek Synergy 2 plate reader and Gen5 software 
v2.01.14.  
Oleate incubation for lipid droplet and nuclear lamina translocation studies 
In order to induce lipid droplet formation, oleic acid: BSA complexes were prepared 
for addition to cell culture medium. First, we prepared a 100 mM sodium oleate solution 
(Sigma-Aldrich, cat#O3880-1G) in distilled water and sonicated on ice (Branson Sonifier 
250 with tapered microtip, Fisher Scientific, Cat#22-309782) under a constant duty cycle 
and output level of 2 for approximately 2 minutes, or until solution reached clarity. We 
then mixed this solution with a 200 mg/ml fatty acid-free BSA (Sigma-Aldrich, A8806-
5G) in PBS and briefly sonicated again until solution was clear. This generated a final 
stock of 100 mg/mL BSA with 10 mM oleate, which we diluted 10-fold in serum-free 
medium (1 x MEM supplemented with non-essential amino acids and 1% L-glutamine) 
for a 1 mM working oleate solution. Cells were incubated in 1 mM oleate medium for 
various timepoints prior to processing for immunofluorescence or lipid droplet staining.   
 
Cell staining and immunofluorescence 
Cell culture was performed using the conditions described above in 12-well plates 
containing sterile 18-mm glass cover slips (VWR, 48380-046). Cells were fixed for 10 
minutes in 4% paraformaldehyde (Sigma-Aldrich, P6148-500G), permeabilized with 0.2% 




(Sigma-Aldrich, A-9647) in 1 x PBS for 1 hour, all at room temperature. Cells were then 
processed for immunofluoresence or lipid droplet staining. 
For immunofluorescence experiments, cells were incubated in primary antibody (anti-
CCTα, Abcam, ab109263) diluted 1:200 in 1% BSA in PBS overnight at 4°C. Cells were 
then incubated in Alexa Fluor 488 or 555 secondary antibodies (Thermo Fisher Scientific, 
A-21428 or A-11008) diluted 1:300 in 1% BSA in PBS for one hour at room temperature. 
For lipid droplet staining, cells were incubated for one hour in BODIPY 493/503 dye 
(ThermoFisher Scientific, Cat#D-3922, stored as 1 mg/mL stock in 100% ethanol at -
20°C) diluted in 1:500 in 1 x PBS.  
Cell nuclei were counterstained with DAPI (Life Technologies, D1306) diluted to 300 
nM in 1 x PBS for 10 minutes at room temperature, followed by mounting with ProLong 
Gold Antifade Mountant (Thermo Fisher Scientific, P36930) on glass slides (Fisher 
Scientific, 12-550-15). Images were obtained using the Zeiss LSM 510 Meta Confocal 
Microscope under 63x oil magnification. 
Lipid Droplet quantification 
Lipid droplet sizes and numbers were quantified as described previously (Aitchison et 
al., 2015).  Using Image J software (v1.47), we converted images to 8-bit, adjusted image 
threshold, and used the “analyze particle” command with a particle size distribution of 20 
to infinity pixels^2 set to exclude on edges.  
Alcian blue staining 
Alcian blue was performed as previously described (Lu et al., 2016), with slight 
modification. Upon reaching ~80% confluency, cells were rinsed in 1xPBS, fixed with 4% 




Blue 8GX (Sigma-Aldrich, A5268-10G) pH 1.0 at 4° C overnight. After briefly washing 
in 1xPBS, cells were lysed in 1% SDS for one hour and absorbance was measured at 605 
nm using the Biotek Synergy 2 plate reader with Gen5 software v2.01.14. 
Lipid standards for mass spectrometry 
The following lipid standards were obtained from Avanti Polar Lipids (Alabaster, AL): 
1,2-dilauroyl-sn-glycero-3-phosphate (sodium salt) (PA 12:0/12:0, PA C12), 1,2-
dilauroyl-sn-glycero-3-phosphocholine (PC 12:0/12:0, PC C12), 1,2-dilauroyl-sn-
glycero-3-phosphoethanolamine (PE 12:0/12:0, PE C12), 1,2-dilauroyl-sn-glycero-3-
phospho-(1’-rac-glycerol) (sodium salt) (PG 12:0/12:0, PG C12), 1,2-dilauroyl-sn-
glycero-3-phospho-L-serine (sodium salt) (PS 12:0/12:0, PS C12), cholesteryl-d7 
palmitate (Cholesterol-d7 ester 16:0, Cholesterol ester d7), N-lauroyl-D-erythro-
sphingosine (C12 Ceramide d18:1/12:0, Cer C12), N-heptadecanoyl-D-erythro-
sphingosine (C17 Ceramide d18:1/17:0, Cer C17), N-lauroyl-D-erythro-
sphingosylphosphorylcholine (12:0 SM d18:1/12:0 SM C12), 1,3-dihexadecanoyl 
glycerol (d5) [1,3-16:0 DG (d5), DG d5], 1,3(d5)-dihexadecanoyl-2-octadecanoyl-
glycerol [TG d5-(16:0/18:0/16:0), TG d5], D-galactosyl-ß-1,1' N-lauroyl-D-erythro-
sphingosine [C12 Galactosyl(ß) Ceramide (d18:1/12:0), GlcCer C12], D-lactosyl-ß-1,1’ 
N-dodecanoyl-D-erythro-sphingosine [Lactosyl (ß) C12 Ceramide, LacCer C12]. We 
purchased APCI positive calibration solution from AB Sciex (Cat. #4460131; Concord, 
Ontario, Canada). 
Stock solutions of PC C12 (12.5 mg/mL), PS C12 (5 mg/mL), and SM C12 (5 mg/mL) 
were dissolved in methanol. Stock solutions of Cer C12 (2.5 mg/mL), Cer C17 (2.5 




(0.25 mg/mL), TG d5 (0.25 mg/mL), LacCer C12 (0.625 mg/mL) and GlcCer C12 (1.25 
mg/mL) were dissolved in dichloromethane/methanol 1:1 (v/v). Finally, cholesterol ester 
d7 was dissolved in dichloromethane. All solutions were stored at -20°C until use. 
Ultrapure water (resistivity > 18 MΩ cm) was used for mass spectrometry experiments. 
Cell culture and lipid extraction for mass spectrometry 
For mass spectrometry experiments, we measured various lipid classes in PCYT1A 
wild-type versus PCYT1A-null HEK293 and ATDC5 cells, or in cultured dermal 
fibroblasts obtained from PCYT1A wild-type controls or SMD-CRD patients 
homozygous for the p.Ser323Argfs*38 variant in PCYT1A. All cells were cultured at 37° 
C under 5% CO2 and passaged using 1 x trypsin-EDTA (Gibco, Cat. #15400-054). 
HEK293 and fibroblast cell lines were cultured in 1 x MEM (Gibco, Cat. #11430-030) 
supplemented with non-essential amino acids (Gibco, Cat. #11140-050), 1% L-glutamine 
(Gibco, Cat. #25030-149), and 10% fetal bovine serum (Gemini Biosciences, Cat. #100-
106). ATDC5 cells were maintained in DMEM/F12 50/50 (Corning Cellgro, Cat. #15-
090-CV) with 1% L-glutamine (Gibco, Cat. #25030-149), and 5% fetal bovine serum 
(Gemini Biosciences, Cat. #100-106), and 1% penicillin-streptomycin (Gibco, Cat. 
#15140-122). Upon reaching ~80% confluency, cells were scraped in ultrapure water, 
pelleted at 1000 x g, resuspended in ultrapure water, and subjected to total protein 
concentration measurements using the BCA protein assay kit (Cat. #23225, Pierce).  Cell 
extracts were stored at -80°C until further processing.  
We isolated lipids from cell extracts using a modified Bligh-Dyer procedure. 200 µg 
protein from each cell suspension was transferred into 1.5 mL plastic centrifuge tubes and 




homogenates by applying short bursts with a sonic dismembrator (Fisher Scientific, 
Waltham, MA). Homogenates were transferred to glass tubes and gently mixed with 800 
µL of ddH2O, for a final volume of 1 mL. We next formed a monolayer by adding 2.9 
mL methanol/dichloromethane (2:0.9, v/v) containing internal standards for 12 lipid 
classes to each sample. We then added 1 mL of ddH2O and 0.9 mL dichloromethane to 
obtain a biphasic mixture, which was incubated at 4
o
C for 30 min and centrifuged at 4 
o
C 
for 10 min at 3000 x g to separate organic and aqueous phases. 1 mL of the organic phase 
was transferred to a 2 mL glass vial and stored at -20
o
C until use. We finally dried 0.5 
mL of the organic layer extract using a nitrogen evaporator (Organomation Associates, 
Inc., Berlin, MA, USA) and re-suspended in 135 µL of running solvent 
(dichloromethane:methanol (1:1) with 5 mM ammonium acetate) containing 5 mg/mL of 
ceramide (C17:0) as an internal standard. All solvents used were HPLC grade. 
Untargeted lipid analysis by MS/MS
ALL
 
Mass spectrometry analyses were performed via MS/MS
ALL
 on a TripleTOF
TM
 5600 
mass spectrometer (AB SCIEX, Redwood City, CA). We applied 50 µL of each lipid 
extraction to the system by direct infusion using a DuoSpray electrospray ionization 
source and autosampler (Shimazu, Canby, OR) at a flow rate of 7 µL/min.  Samples were 
run in duplicate in the positive ion mode. A dichloromethane: methanol solution (1:1, v/v) 
with 5 mM ammonium acetate was used as the running solvent. We used a mass 
resolution of ∼30 000 for TOF MS scans and ∼15 000 for product ion scans in high 
sensitivity mode, and automatically calibrated using APCI positive calibration solution 
delivered via calibration delivery system (AB Sciex) after every 10 sample injections. We 




curtain gas 30 psi, temperature 150
o
C, positive ion spray voltage +5200 V, declustering 
potential of 80V and collision energy of 10V. Initial TOF MS scanning provided an 
overview of total lipid content at an accumulation time of 5s. Precursor ions were 
selected by sequential 1 Da mass steps from 200.050 to 1200.050 m/z. Analytes in each 1 
Da step were introduced into the collision chamber, and fragments were identified by 
TOF with a scan range of 100-1500 m/z (accumulation time of 300 ms). The collision 
energy for each MS/MS step was 40eV. In addition, a pooled sample containing extracts 
from all groups was run 8 times for lipid identification and subsequent selection of 
targeted lipids. All data was acquired using Analyst 1.7 TF (AB SCIEX, Concord, ON, 
Canada). 
Mass spectrometry data processing and analysis 
The TOF MS and MS/MS
ALL
 data obtained from individual samples and pooled 
samples were aligned post-acquisition to internal standards using Analyst 1.7 TF. We 
conducted broad assignment and identification of lipids on the aligned data from pooled 
samples using LipidView
TM
 software (v1.3 Beta, AB SCIEX, Concord, ON, Canada). To 
reduce false-positive identifications due to instrumental noise, lipids whose MS/MS 
fragment peaks appeared in at least 7 of 8 pooled runs were considered for further 
analysis. We then calculated the coefficient of variation (CV) of the fragment peak 
intensity for each lipid relative to the internal standard for this class of lipid obtained over 
multiple runs. Lipids with CVs <20% were considered reliable and used as targeted lipids 
in order to identify lipids of these classes in experimental samples using LipidView
TM
. 
We calculated CV values and generated targeted lipid lists using a custom in-house 




was used to identify lipids in experimental samples by comparing to the targeted lipid list 
described above. Peak intensities were corrected using internal standards for each class of 
lipid, and we averaged duplicates within each sample for further analysis. To ensure that 
data could be statistically analyzed, any zero-value intensities were replaced by 0.000001. 
We then proceeded with additional data analysis using R 3.4.2 (Bioconductor). Data were 
log-transformed, z-score normalized, and exponentially transformed so that all values 
were positive. In order to compare each lipid between PCYT1A wild-type and variant cell 
lines of each group (ATDC5, HEK293, or fibroblast cell lines), we used Welch’s two-
sample t-test.  
Statistical procedures 
All statistical analyses were performed using R 3.2.4 (Bioconductor).  Multiple 
group comparisons were done using Tukey’s Honest Significant Difference test. No 
outliers were removed for statistical analyses.  
Results 
Measurement of CCTα steady state levels and PC incorporation rates 
Western blot analysis of CCTα steady state levels in cultured fibroblasts of five SMD-
CRD patients (4 probands and one affected sibling) revealed reduced CCTα steady state 
levels in all patient cell lines as compared to wild-type controls, with the level of 
reduction varying according to patient genotype (Figure 3A). Fibroblasts homozygous for 
the p.Ala99Val variant had the mildest reductions in CCTα steady state levels (~75% 
wild-type levels), followed by p.Glu129Lys homozygotes (~30% wild-type levels). 




~10% of wild-type CCTα levels, and similar levels were observed in cells compound 
heterozygous for the p.Ser323Argfs*38/p.Ser114Thr variants.  
To assess PC synthesis, we measured continuous incorporation of [³H]-choline into PC 
in intact fibroblasts over 2 hours. Consistent with the results of our western blotting 
experiments, p.Ala99Val homozygotes had the mildest impairments in PC incorporation 
(54% of wild-type), whereas homozygotes for the p.Ser323Argfs*38 or p.Glu129Lys 
alleles had only 22% of wild-type incorporation levels, and compound heterozygotes for 
the p.Ser323Argfs*38/p.Ser114Thr alleles had 33% of wild-type incorporation.  
CCTα membrane translocation in putative cell models 
In order to assess the utility of several cell models for studying CCTα variants, we first 
analyzed CCTα localization in response to oleate treatment. Previous studies have shown 
that oleate stimulation can induce CCTα translocation to the nuclear lamina in CHO cells 
and in HEK293 cells, although results are variable depending on the report and the cell 
line tested (Aitchison et al., 2015; Gehrig et al., 2008; Lagace & Ridgway, 2005). Under 
our experimental conditions, oleate failed to stimulate translocation of CCTα to 
membranes in wild-type fibroblasts or in CHO cells, but did induce membrane 
translocation in wild-type HEK293 cells. Based on this finding, we decided to move 
forward with additional cellular modeling in HEK293 cells to examine consequences of 
PCYT1A variants on cellular phenotypes. 
Lipid droplet analyses 
In cells from Drosophila, mice, and rats, deficiency of CCTα orthologs results in 
formation of fewer and larger lipid droplets than in control cells in response to oleate 




we hypothesized that SMD-CRD patient fibroblast cells would also develop fewer and 
larger lipid droplets in response to oleate treatment. However, this was not the case. The 
sizes and numbers of lipid droplets in both wild-type and SMD-CRD patient fibroblast 
cell lines were highly heterogeneous, and SMD-CRD patient fibroblasts 
(p.Ser323Argfs*38 homozygotes) failed to show significant differences in lipid droplet 
numbers or sizes as compared to control cells (Fig. 4A and 4C).  Interestingly, however, 
PCYT1A-null HEK293 cells generated fewer and larger lipid droplets than their wild-type 
counterparts in response to oleate loading (Fig. 4B and 4D). Transfection with wild-type, 
p.Ala99Val, and p.Tyr240His PCYT1A cDNAs, but not empty vector cDNA, rescued 
lipid droplet phenotypes in PCYT1A-null cells (Fig. 4E).  
Proliferation studies in HEK293 cells 
Interestingly, PCYT1A-null HEK293 cells proliferated at normal rates as compared to 
wild-type cells (Fig. 5A). We hypothesized that this might be attributable to exogenous 
serum lipid uptake in PCYT1A-null cells, so we next determined the effects of culturing 
cells in delipidized serum.  Both wild-type and PCYT1A-null HEK293 cells grew slower 
in delipidized serum as compared to normal serum, but surprisingly PCYT1A-null 
HEK293 cells actually grew more effectively than their wild-type counterparts in 
delipidized serum (Fig. 5A).  
Effects of Pcyt1a knockout on chondrocyte proliferation and differentiation 
 To evaluate the utility of ATDC5 pre-chondrocytes as a model system, we first 
assessed their steady-state CCTα levels at baseline and over the course of 21 days of 
chondrocyte differentiation by western blot analysis. CCTα protein was expressed 




expression over the 21-day differentiation timecourse (Fig. 6A). Next, we generated 
Pcyt1a-null ATDC5 cell lines using genome editing and assessed the consequences of 
Pcyt1a loss-of-function on chondrocyte proliferation and differentiation.  Similar to our 
observations in HEK293 cells, Pcyt1a-null ATDC5 cells proliferated at normal rates as 
compared to their wild-type counterparts (Fig. 5B). However, Pcyt1a-null ATDC5 cells 
actually differentiated into chondrocytes more quickly than their wild-type counterparts 
(Fig. 6B).   
Untargeted lipidomic studies 
To assess global changes in lipid metabolism in SMD-CRD patient-derived skin 
fibroblasts (p.Ser323Argfs*38 homozygotes) and in PCYT1A-null HEK293 or ATDC5 
cells as compared to their wild-type counterparts, we conducted untargeted mass 
spectrometry on ~1000 distinct lipids.  In total, the levels of ~75-200 lipids were 
significantly increased or decreased in the PCYT1A-null or SMD-CRD condition for each 
cell line tested, and the specific lipids altered were largely variable depending on the cell 
type tested, with one exception. The levels of several individual LPCs (Fig. 7A) were 
significantly decreased in PCYT1A-null HEK293 cells (LPCs 16:1, 18:1, 18:2, 20:0, 20:3, 
20:4, 20:5, 22:5, and 22:6) and in SMD-CRD patient fibroblasts (LPCs 16:0, 16:1, 16:3, 
18:1, 18:2, 20:1, 20:4, 22:4, and 22:5). Notably, levels of five identical LPCs (LPCs 16:1, 
18:1, 18:2, 20:4, and 22:5) were reduced in both PCYT1A-null HEK293 cells and in 
SMD-CRD patient fibroblast cell lines as compared to controls. 
We first examined whether the proportions of specific lipid classes in each cell line 
was altered in PCYT1A-null or SMD-CRD conditions as compared to wild-type controls. 




ester, ceramide, desmosteryl ester, diacylglycerol, galactosylceramide, lactosylceramide, 
lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, 
lysophosphatidylserine, monoakyldiacylglyceride, phosphatidic acid, 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, 
phosphatidylserine, sphingomyelin, or triacylglyceride. Some lipid classes were not 
represented in all cell lines tested.  In PCYT1A-null ATDC5 cells as compared to their 
wild-type counterparts, we observed significant decreases in the overall proportions of 
lysophosphatidylcholines (4-fold) and lysophosphatidylethanolamines (2-fold). In SMD-
CRD patient cells homozygous for the p.Ser323Argfs*38 variant as compared to wild-
type controls, we observed significant increases in the overall proportions of 
diacylglycerol (1.9-fold) and phosphatidylethanolamine (1.6-fold). Finally, in PCYT1A-
null HEK293 cells as compared to their wild-type counterparts, we observed significant 
decreases in the proportions of lysophosphatidylcholine (2-fold) and phosphatidylcholine 
(2.5-fold), as well as significantly increased proportions of galactosylceramide (1.9-fold), 
lactosylceramide (2-fold), and lysophosphatidylserine (2.5-fold).  
Next, we analyzed whether the ratios of specific lipid classes were altered in PCYT1A-
null or SMD-CRD patient cells as compared to wild-type controls for each cell type.  
First, we found that sphingomyelin:ceramide (SM:Cer) ratios were not significantly 
altered in any of the PCYT1A-null or SMD-CRD patient cell lines as compared to their 
wild-type counterparts (data not shown).  However, 
phosphatidylcholine:phosphatidylethanolamine (PC:PE) ratios were reduced significantly 
by 2-3 fold in PCYT1A-null HEK293 cells and in SMD-CRD patient fibroblast cell lines 





Through western blot analyses PC incorporation assays, we determined that all SMD-
CRD patient-derived dermal fibroblasts tested were hypomorphic to varying degrees, 
ranging from 10-75% of wild-type steady state CCTα protein levels and 22-54% of wild-
type PC incorporation.  Surprisingly, the level of reduction in steady-state CCTα or PC 
incorporation does not appear to correlate with the severity of patients’ phenotypes. 
Fibroblasts homozygous for p.Ala99Val had the mildest biochemical phenotype of all 
variants tested, both in their CCTα steady state levels (75% of wild-type) and PC 
incorporation (54% of wild-type). Because the p.Ala99Val allele decreased PC 
incorporation more severely than steady-state expression, we conclude that this allele 
reduces the catalytic activity of CCTα independently of its effects on protein production 
or stability.  This conclusion is further supported by the location of the affected amino 
acid in the crystal structure of the orthologous rat CCTα protein: the alanine residue falls 
adjacent to a glutamine which is involved in CDP coordination, and hence is important 
for catalytic activity (J. Lee et al., 2009). 
Other alleles reduced steady state levels of CCTα and PC incorporation much more 
severely:  for instance, fibroblasts homozygous for the p.Ser323Argfs*38 allele had only 
10% of the steady state CCTα and 22% of the PC incorporation levels of wild-type 
fibroblasts.  We did not expect this allele to result in complete loss of CCTα expression, 
since the generated termination codon is C-terminal to the penultimate exon junction and 
therefore is not predicted to be subject to nonsense-mediated mRNA decay.  However, 
the strong decrease in steady state CCTα coupled with less severe reductions in PC 




increased catalytic activity resulting from its modified C-terminus, which typically 
regulates activation of the enzyme.  
Compound heterozygous fibroblasts for p.Ser323Argfs*38/p.Ser114Thr alleles had 
only 14% of wild-type steady state CCTα but 33% of wild-type PC incorporation.  The 
protein levels in this cell line were only slightly higher than those of p.Ser323Argfs*38 
homozygotes, indicating that the p.Ser114Thr allele has similarly adverse consequences 
on protein production or stability, at least when in combination with the 
p.Ser323Argfs*38 allele. However, similar to p.Ser323Argfs*38 homozygotes, the 
residual CCTα protein in compound heterozygotes seems to have normal or even 
increased activity as compared to wild-type protein. Finally, fibroblasts homozygous for 
p.Glu129Lys had ~30% of wild-type steady-state CCTα levels and similar levels of PC 
incorporation (22% of wild-type), indicating that this variant protein is unstable and has 
normal or only mildly reduced CCTα activity. This glutamic acid residue falls in an α-
helix at the CCTα dimerization interface which is part of a larger series of α-helices and 
β-strands comprising a Rossman fold domain (J. Lee et al., 2009). It is possible that this 
variant destabilizes CCTα by decreasing its capacity to dimerize. 
Contrary to our expectations based on prior studies in Drosophila, mouse, and rat cell 
lines (Aitchison et al., 2015; Guo et al., 2008; Krahmer et al., 2011), SMD-CRD patient 
fibroblasts (p.Ser323Argfs*38 homozygotes) failed to show significant differences in 
lipid droplet numbers or sizes as compared to controls, indicating that oleate loading does 
not induce an abnormal lipid droplet phenotype in cells with this genotype.  Of note, 
p.Ser323Argfs*38 homozygous fibroblasts had the most severe reductions of all SMD-




in phosphatidylcholine incorporation (~22% wild-type levels), so the absence of a lipid 
droplet phenotype in our experiments was surprising. This may be because the 
mechanism for regulating lipid droplet sizes and numbers is not conserved in human 
fibroblasts. Alternatively, it is possible that complete ablation of CCTα protein 
expression is required for lipid droplet phenotypes to manifest; indeed, SMD-CRD 
patient fibroblasts retained some residual CCTα expression and activity, which could be 
sufficient to normalize lipid droplet formation. Consistent with previous publications, 
PCYT1A-null HEK293 cells generated fewer and larger lipid droplets than did wild-type 
HEK293 cells in response to oleate loading, suggesting again that CCTα-mediated lipid 
droplet regulation may be cell-type specific in cultured human cell lines, or that complete 
ablation of PCYT1A expression may be required in order for lipid droplet phenotypes to 
manifest. Transfection with wild-type, p.Ala99Val, and p.Tyr240His PCYT1A cDNAs, 
but not empty vector cDNA, rescued lipid droplet phenotypes in PCYT1A-null cells. This 
may indicate that these variants in the catalytic or membrane-binding domains of CCTα 
provide ample enzyme activity and PC production to generate lipid droplets normally; 
this interpretation would be consistent with our findings in SMD-CRD patient fibroblasts, 
in which even small residual amounts of functional CCTα are sufficient to regulate lipid 
droplet formation normally.  However, we also recognize that cDNA expression was 
driven by a CMV promoter in our transfection studies, which may simply normalize lipid 
droplet phenotypes by PCYT1A overexpression. 
Given that Pcyt1a-null mice are embryonic lethal and CHO MT-58 cells undergo 
apoptosis (Cui et al., 1996; Sweitzer & Kent, 1994; L. Wang et al., 2005), we were 




normal and proliferated at normal rates as compared to their wild-type counterparts. 
However, these results are consistent with findings that Pcyt1a-null mouse peritoneal 
macrophages grow normally under standard cell culture conditions due to compensatory 
upregulation of a specific isoform of Pcyt1b (D. Zhang et al., 2000).  Interestingly, 
however, these Pcyt1a-null mouse macrophages had increased susceptibility to cell death 
upon loading with free cholesterol, suggesting that additional stressors may be required to 
evoke cell death in CCTα-deficient cell lines. Furthermore, we found that PCYT1A-null 
HEK293 cells proliferated more quickly than their wild-type counterparts when cultured 
in delipidized serum.  This suggests that growth rates are normalized independently of 
exogenous lipid uptake from serum in these cells, and that PCYT1A-null HEK293 cells 
may have a growth advantage over their wild-type counterparts when grown in conditions 
devoid of exogenous lipids, perhaps by upregulation of compensatory pathways for PC 
production. 
Using untargeted mass spectrometry, we were able to investigate changes in lipid 
species apart from those directly implicated in the Kennedy pathway. We found that a 
broad array of lipids are increased or decreased in PCYT1A-null HEK293 or ATDC5 
cells or SMD-CRD patient fibroblast cell lines as compared to controls, and the altered 
lipids were often cell-type specific.  However, we noticed a few trends that replicated in 
more than one of the three cell lines tested.  First, total PC:PE ratios were significantly 
decreased in PCYT1A-null HEK293 and in SMD-CRD patient fibroblast cell lines as 
compared to controls.  Decreased PC:PE ratios have previously been associated with the 




Li et al., 2006), so it is possible that decreased ratios of these lipids have broad adverse 
consequences.  
In addition, we found that several LPCs were significantly decreased in both PCYT1A-
null HEK293 and in SMD-CRD patient fibroblast cell lines as compared to the 
corresponding control cell lines. Interestingly, five of these decreased LPCs had the same 
acyl chain compositions in both cell lines:  LPC 16:1, 18:1, 18:2, 20:4, and 22:5. 
Decreased LPCs could be attributable either to increased conversion of LPC into PC by 
LPCAT or to decreased conversion of PC into LPC by PLA2.  Previous studies in COS 
cells and in CHO cells have shown that CCTα overexpression increases LPC levels by 
promoting PLA2-mediated PC catabolism (Walkey, Kalmar, & Cornell, 1994; Barbour, 
Kapur, & Deal, 1999), so it is possible that decreased activity by this pathway is also 
responsible for decreases in LPC in our cell lines.  However, recent studies have also 
demonstrated increased Lpcat4 mRNA expression and activity toward LPC acyl chains 
18:1, 18:2, 20:4, and 22:6 during the late stages of chondrocyte differentiation in ATDC5 
cells (Tabe et al., 2017). Notably, LPCs with three of these four acyl chains (18:1, 18:2, 
and 20:4) were decreased in SMD-CRD patient fibroblast cell lines, and all four were 
decreased in PCYT1A-null HEK293 cells as compared to wild-type controls in our study.  
The mean levels of these and other individual LPCs were also decreased in Pcyt1a-null as 
compared to wild-type ATDC5 cells, but none of these decreases approached statistical 
significance. This may be due in part to the small sample size of ATDC5 cells measured 
in our study, so we suggest further investigation of LPCs in this cell type for future 




decreases in overall LPC content in both PCYT1A-null HEK293 cells and ATDC5 cells 
as compared to wild-type controls.   
Decreased LPCAT expression or activity may also be supported by our finding that 
Pcyt1a-null ATDC5 cells have increased rates of chondrocyte differentiation as 
compared to wild-type controls.  Lpcat4 knockdown has been associated with decreased 
rates of chondrocyte differentiation in ATDC5 cells (Tabe et al., 2017), so it is possible 
that compensatory upregulation of Lpcat4 expression or activity contributes to the 
increased rate of chondrocyte differentiation in Pcyt1a-null ATDC5 cells.  Changes in 
chondrocyte differentiation rates have also been observed in previous studies of other 
skeletal dysplasias.  For instance, ATDC5 cells expressing the variant responsible for 
achondroplasia have slowed rates of chondrocyte differentiation, whereas mice null for 
parathyroid hormone-related protein have accelerated rates of chondrocyte differentiation 
(Lanske et al., 1996; Matsushita et al., 2013).  Our results suggest that SMD-CRD may be 
another phenotype for which perturbed rates of chondrocyte differentiation contribute to 
skeletal dysplasia. 
The overall proportions of lipids represented in each SMD-CRD variant or PCYT1A-
null cell line were also altered, but the nature of the alterations varied among cell types.  
As mentioned previously, the only lipid whose overall cellular content was decreased in 
two cell types was LPC, which was present in lower proportions in PCYT1A-null 
HEK293 and ATDC5 cell lines as compared to corresponding wild-type controls.  In 
Pcyt1a-null ATDC5 cells, we also observed decreases in overall LPE content, suggesting 
potential upregulation of LPE acyltransferase (LPEAT) or downregulation of PLA2. In 




compensatory pathways for PC production may not be as robust in this cell type as in 
others. PCYT1A-null HEK293 cells also had increased content of LPS, 
galactosylceramide, and lactosylceramide.  However, the reasons or implications for 
increased levels of these lipids are unclear. Both galactosylceramide and 
lactosylceramide are formed from ceramide, which can combine with PC to form 
sphingomyelin in a reaction catalyzed by sphingomyelin synthase. Perhaps decreased PC 
production by the Kennedy pathway promotes downregulation of sphingomyelin 
synthase in an attempt to maintain cellular PC, and in turn promotes increases in other 
ceramide metabolic pathways such as those required for galactosylceramide and 
lactosylceramide production. In homozygous p.Ser323Argfs*38 fibroblasts, the 
proportions of DAG and PE were increased as compared to wild-type fibroblasts.  
Increased proportions of DAG might be expected, given that SMD-CRD cells have 
decreased production of CDP-choline, which normally combines with DAG to form PC 
in the final step of the Kennedy pathway. However, increased proportions of PE were not 
expected a priori and suggest that in SMD-CRD fibroblasts, upregulation of the PEMT 
pathway is not likely a major means for compensatory PC production. 
Overall, our results indicate that partial or complete loss of PCYT1A in ATDC5, 
HEK293, or fibroblast cell lines leads to decreased PC synthesis by the Kennedy pathway 
and cell-type specific secondary dysregulation of diverse additional lipid metabolic 
pathways, which manifests in lipid droplet phenotypes in HEK293 cells but not SMD-
CRD patient fibroblasts.  Our results also suggest involvement of Pcyt1a in chondrocyte 
differentiation but not proliferation or morphology.  We suggest that a careful side-by-




lipodystrophy in a range of cell types would be informative for dissecting further tissue-
specific consequences of these alleles.  
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Chapter 5 Figures 
Figure 1. Diagram of all known SMD-CRD alleles to-date. Both previously described 
and novel SMD-CRD patient variants are mapped to their corresponding CCTα protein 
domains.  Note that most variants are missense and fall within the catalytic domain. NLS-





Figure 2. Kennedy pathway and related pathways for PC production. Choline (Cho) 
is taken in exogenously from the diet and transported across the plasma membrane into 
the cytosol, where it becomes phosphorylated by choline kinase to produce 
phosphocholine (P-Cho).  Phosphocholine is converted into CDP-choline (CDP-Cho) in a 
reaction catalyzed by CTP:phosphocholine cytidylyltransferase (CCT), which is 
combined with diacylglycerol (DAG) to form phosphatidylcholine (PC).  Phospholipase-
A2 (PLA2) converts PC into lyso-phosphatidylcholine (LPC), which can be converted into 
PC once more in a reaction catalyzed by lysophosphatidylcholine acyltransferase 
(LPCAT).   PC can also be derived from sequential methylation of 
phosphatidylethanolamine (PE) by phosphatidylethanolamine N-methyltransferase. The 
red rectangle indicates the location of the block in PC synthesis in SMD-CRD. 
Phosphatidylethanolamine can also be interconverted to lysophosphatidylethanolamine 






Figure 3. Western blot and PC incorporation assays of SMD-CRD patient 
fibroblasts. A) Representative immunoblot showing reduced protein expression of CCTα 
relative to loading control β-actin in cultured skin fibroblasts of five SMD-CRD patients 
as compared to wild-type controls, with the level of reduction varying according to 
patient genotype. Protein levels ranged from ~10-75% of wild-type CCTα. B) To assess 
PC synthesis, we measured continuous incorporation of [³H]-choline into PC in intact 
fibroblasts over 2 hours. Cell lines again had variable PC incorporation levels, ranging 
from 22-54% of wild-type. Error bars represent standard deviation.  n=3 biological 








Figure 4. Lipid droplet experiments. Lipid droplet (LD) formation was induced by 
oleic acid loading and visualized with BODIPY staining.  LD size and number were 
quantified using “analyze particle” command in ImageJ (v1.47). A and B) Neither LD 
size (p=0.43) nor number (p=0.87) differed between control and SMD-CRD patient 
fibroblasts. C and D) PCYT1A-null HEK293 cells have fewer and larger LDs than control 
cells. E) LD sizes and numbers are rescued by transfection with PCYT1A WT, 
p.Ala99Val or p.Tyr240His cDNAs but not corresponding empty vector controls. n=200 
cells from 4 experimental trials. Error bars represent SD. Welch Two Sample t-test for 








Figure 5. PCYT1A-null HEK293 and ATDC5 cells have normal proliferation rates. 
A) Wild-type and PCYT1A-null HEK293 cells were grown in either normal serum or 
delipidized serum up to 144 hours and counted every 24 hours. Growth rates were 
comparable for both cell lines under normal serum; however, PCYT1A-null HEK293 cells 
actually grew more rapidly in delipidized serum than their wild-type counterparts. B) 
Undifferentiated wild-type or Pcyt1a-null ATDC5 cells were grown for 5 days and 
counted every 24 hours using absorbance-based cell counting. At all time points, wild-







Figure 6. Involvement of Pcyt1a in ATDC5 chondrocyte differentiation. A) Western 
blot analysis shows that CCTα steady-state levels remain stable over the course of 21 
days of chondrocyte differentiation. B) Rates of chondrocyte differentiation are increased 
in Pcyt1a-null ATDC5 cells, as measured by absorbance reading of Alcian blue staining. 







Figure 7. Untargeted lipidomics reveal decreases in LPCs and in PC:PE ratio in 
SMD-CRD patient fibroblasts and PCYT1A-null HEK293 cells. A) Several specific 
lysophosphatidylcholine (LPC) species (acyl chain compositions denoted) were 
decreased in both SMD-CRD patient fibroblasts and PCYT1A-null HEK293 cells as 
compared to wild-type controls. B) Ratios of total phosphatidylcholine (PC) to 
phosphatidylethanolamine (PE) were decreased in both SMD-CRD patient fibroblasts 
and PCYT1A-null HEK293 cells but not Pcyt1a-null ATDC5 cells as compared to wild-







Chapter 6: Conclusion 
From this work, we have seen that numerous challenges exist for the detection of 
variants from next-generation sequencing studies as well as the functional 
characterization studies that follow in their wake. However, as time has progressed, novel 
methodological developments and analytic strategies have become available which 
increase our ability to identify and characterize genetic variants underlying Mendelian 
disorders.  For instance, long-read sequencing methodologies are evolving and becoming 
increasingly more affordable, so we can sequence larger blocks of DNA and better detect 
structural variants, copy number variants, or disease haplotypes. Whole genome 
sequencing is also becoming more cost-effective, so as we approach saturation for variant 
detection in the exome, we can turn toward genome sequencing for families whose causal 
variants were not detectable via exome sequencing. In addition, methods for variant 
detection are progressing—particularly for copy number and structural variants—
allowing us to revisit existing sequence data with new tools. Alternatively, we can couple 
existing methods such as linkage analysis with next-generation sequencing in order to 
solve a greater proportion of cases.   
Researchers and clinicians are increasingly recognizing that families with each 
rare Mendelian disorder are limited, as are the resources with which to study them. 
Consequently, collaborative efforts are increasing, both through traditional mechanisms 
(see Chapter 2 for an example) and through tools such as GeneMatcher which facilitate 
genetic matchmaking on a larger scale (Sobreira, Schiettecatte, Valle, & Hamosh, 2015). 
Moreover, many groups are now integrating mRNA expression data from individual 




GTEx project) as well as proteomic studies to prioritize genes which are mutated and also 
have altered expression profiles (Genotype-Tissue Expression Project, 
www.gtexportal.org; Allen Brain Atlas, www.brain-map.org).  
Large databases harboring variant frequency information (e.g. ExAC and 
gnomAD) as well as variant-associated phenotypic information (e.g. ClinVar) have 
enhanced our ability to filter variants based on their population frequencies or known 
clinical associations (Landrum et al., 2014; Lek et al., 2016). Many countries whose 
populations were previously underrepresented in genetic databases are also undertaking 
large-scale sequencing projects, which will enrich our understanding of human variation 
more globally.  Moreover, our knowledge of which genes are essential for life in humans 
or other model organisms is also evolving through resources like the knockout mouse 
project and the human knockout project (Lloyd, 2011; Saleheen et al., 2017), which 
demonstrate the consequences of deleting specific genes.  The Precision Medicine 
Initiative is also underway, which will elucidate relationships between genomics and 
phenotypic outcomes as they evolve over time (Terry, 2015).  
Moreover, new computational and statistical methods are being developed that 
can be applied to sequencing studies. Some of these tools include improved splice site 
detection algorithms (M. Lee et al., 2017), catalogs of noncoding genetic elements such 
as those developed by the ENCODE project (Dunham et al., 2012), and tools for the 
spatial clustering of de novo missense variants (Lelieveld et al., 2017).  In addition, we 
can apply more robust statistical methods such as genetic burden tests for cohort analyses 




oligogenic contributors to Mendelian disease have not yet been developed, such an 
advance is anticipated going forward.  
Various methods are currently available for prioritization of candidate genes and 
variants, such as genic intolerance and CADD scores (Kircher et al., 2014; Petrovski et 
al., 2013), and additional scores have been developed for applications such as ranking 
variants on a genome-wide level or based on the protein domains in which they fall 
(Gussow, Petrovski, Wang, Allen, & Goldstein, 2016; Smedley et al., 2016; Wiel, 
Venselaar, Veltman, Vriend, & Gilissen, 2017).  
As a more robust catalog of candidate genes and variants is developed, we will be 
faced with the need to characterize their functional consequences at the bench.  As 
demonstrated in Chapter 5, this can be quite challenging and may reveal unanticipated 
mechanistic complexities that take time to unravel.  However, several tools now exist that 
improve our ability to functionally characterize variants and may ease this process in the 
future. For instance, we can now generate knockout or knock-in models fairly quickly 
using CRISPR/Cas9-mediated genome editing.  This method may ameliorate the 
challenges of allelic heterogeneity by enabling us to model specific alleles, or even to 
examine the functional consequences of all possible changes in a gene through saturation 
genome editing (Findlay, Boyle, Hause, Klein, & Shendure, 2014). Genome editing can 
be applied to various model systems, including cell lines, animal models, and induced 
pluripotent stem cells, which together give us a broadly expanded repertoire for 
understanding the functional consequences of genetic variation.   
In the end, next-generation sequencing endeavors, increasingly sophisticated 




for patients with Mendelian disorders, their families, and society at large. We now have a 
wide array of disorders which we can target with pharmaceutical interventions or gene 
therapies in order to ameliorate phenotypic manifestations, and expect this will bolster 
our understanding of the biological systems and mechanisms underlying these and other 
disorders.  Furthermore, the knowledge we gain from sequencing will enhance genetic 
counseling, carrier screening, and prenatal testing, and perhaps even lead to phenotypic 
expansion for known disorders.  Our efforts in Mendelian genetics have been 
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TEACHING AND MENTORSHIP 
Graduate Course in Advanced Topics in Human Genetics          Nov 2014-May 2015 
 Johns Hopkins University  
Teaching Assistant 
• Worked with course instructors and a fellow graduate student to shape course 
content, manage the course, and answer students’ questions. 
• Led weekly discussion sections, wrote and graded assignments and exams, 
developed review materials, and coordinated course logistics. 
 
Predoctoral Training Program in Human Genetics               Sept 2015-Dec 2017 




Graduate and undergraduate student mentor 
• Mentor undergraduate and junior graduate students in their laboratory rotations 
and thesis projects. 
• Develop projects for students and supervise progress in lab. 
• Help students design, conduct, and troubleshoot experiments. Assist them in 
developing abstracts, posters, and oral presentations. Provide ongoing 
resources for scientific and career development.   
 
Thomas Jefferson High School for Science and Technology          June 2010-Aug 2012 
McLean, Virginia  
High school student mentor           
• Taught high school students techniques in molecular biology, supervised 
laboratory progress, and offered troubleshooting assistance. 
• Helped students develop written and oral presentations, write scientifically, 
edit college applications, and navigate educational and career development. 
 
Mentees: 
High school students: Alan Barte, Rishav Adhikari, Riley Ennis 
Undergraduate students: Adam Uppendahl, Sophie Nguyen 
Graduate students: Arianna Franca, Sarah Robbins, Anh-Thu Lam       
 
CONFERENCE PRESENTATIONS 
Assessment of incidental findings in whole exome sequencing data from the Baylor-
Hopkins Center for Mendelian Genomics. Platform Presentation. American Society of 
Human Genetics 2013. 
Abnormal phospholipid metabolism due to variants in PCYT1A causes 
spondylometaphyseal dysplasia with cone-rod dystrophy. Poster Presentation. Hopkins 
MD-GEM Genetics Research Day 2014. 
Assessment of incidental findings in whole exome sequencing data from the Baylor-
Hopkins Center for Mendelian Genomics. Poster Presentation. Hopkins MD-GEM 
Genetics Research Day 2014.  
Abnormal phospholipid metabolism due to variants in PCYT1A causes 
spondylometaphyseal dysplasia with cone-rod dystrophy. Poster Presentation. American 
Society of Human Genetics 2014.  
Strategy for Generating and Characterizing a Zebrafish Knockout Model of 
Spondylometaphyseal Dysplasia with Cone-rod Dystrophy. Poster Presentation. Hopkins 




Strategy for Generating and Characterizing a Zebrafish Knockout Model of 
Spondylometaphyseal Dysplasia with Cone-rod Dystrophy. Poster Presentation. 
American Society of Human Genetics 2015. 
Phenotypic characterization of cell lines from patients with spondylometaphyseal 
dysplasia with cone-rod dystrophy (SMD-CRD). Poster Presentation. American Society 
of Human Genetics 2016. 
Investigation of novel genetic bases for strabismus using linkage analysis and next-
generation sequencing. Hopkins MD-GEM Genetics Research Day 2017. 
Investigation of novel genetic bases for strabismus using linkage analysis and next-
generation sequencing. Poster Presentation. American Society of Human Genetics 2017. 
 
PROFESSIONAL SOCIETY MEMBERSHIPS 
Member, American Society of Human Genetics                     June 2013-Present 
